Please sign in to follow a disease.
Reproductive system disorder
MONDO:0005039A disease involving the reproductive system.
Also known as: disease of reproductive system, disease or disorder of reproductive system, disorder of reproductive system, genital disorders, reproductive disease, reproductive system disease, reproductive system disease or disorder, reproductive system disorder
7371 clinical trials for this condition and its sub-types.
Follow this condition — get notified about new trialsSub-types
Broader categories
-
Experimental HIV vaccine trial ends early – what we know
⭐️ VACCINE ⭐️ TerminatedThis early-stage trial tested an experimental HIV vaccine in 44 healthy adults to see if it was safe and triggered an immune response. The vaccine uses a piece of the HIV virus (fusion peptide) to train the body's defenses. The study was terminated early, so the full results are …
Phase: PHASE1 • Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) • Aim: ⭐️ VACCINE ⭐️
Last updated Jun 27, 2026 12:23 UTC
-
Could a second dose of steroids help premature babies breathe easier?
Disease control TerminatedThis study investigates whether giving a repeat course of betamethasone, a steroid, to pregnant women with preterm premature rupture of membranes (PPROM) can improve health outcomes for their premature babies. The main goal is to see if it shortens the baby's stay in the neonatal…
Phase: PHASE2, PHASE3 • Sponsor: The University of Texas Medical Branch, Galveston • Aim: Disease control
Last updated Jul 02, 2026 00:00 UTC
-
New hope for rare hunger disorder: drug shows promise in Long-Term trial
Disease control TerminatedThis study tests whether ARD-101 can safely reduce extreme hunger and food-related behaviors in people with Prader-Willi syndrome over 12 months. About 90 participants who completed a prior study will take the drug daily and visit the clinic regularly. The goal is to improve qual…
Phase: PHASE3 • Sponsor: Aardvark Therapeutics, Inc. • Aim: Disease control
Last updated Jul 02, 2026 00:00 UTC
-
Could a common diabetes drug shrink prostate tumors?
Disease control TerminatedThis early-stage trial is testing whether dapagliflozin (Farxiga), a drug used for diabetes and heart failure, is safe and tolerable when taken for four weeks before prostate removal surgery in men with localized prostate cancer. The study will also look for signs that the drug m…
Phase: PHASE1 • Sponsor: Washington University School of Medicine • Aim: Disease control
Last updated Jul 02, 2026 00:00 UTC
-
Peer support may boost HIV treatment success in people who inject drugs
Disease control TerminatedThis study tests whether adding peer-based counseling to standard HIV and opioid treatment helps people who inject drugs stay on their medications and achieve viral suppression. Participants receive either enhanced usual care or extra support from a peer counselor. The goal is to…
Phase: NA • Sponsor: Yale University • Aim: Disease control
Last updated Jul 01, 2026 00:00 UTC
-
New drug combo for tough prostate cancer shows early promise, but trial halted
Disease control TerminatedThis early-phase study tested a combination of two oral drugs, abemaciclib and darolutamide, in 10 men with metastatic castration-resistant prostate cancer that had spread despite standard hormone therapy. The main goal was to check safety and side effects. The trial was terminat…
Phase: PHASE1 • Sponsor: Eli Lilly and Company • Aim: Disease control
Last updated Jun 28, 2026 00:00 UTC
-
New hope for rare uterine cancer? trial tests avastin with chemo
Disease control TerminatedThis phase 3 trial tested whether adding bevacizumab (Avastin) to standard chemotherapy (docetaxel and gemcitabine) helps people with advanced or recurrent uterine leiomyosarcoma. The study enrolled 107 participants but was terminated early. Researchers measured how long patients…
Phase: PHASE3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
Experimental cancer drug tested in early trial, but study stopped early
Disease control TerminatedThis early-stage trial tested an experimental drug called PF-08052666 in 19 people with advanced solid tumors like lung, ovarian, and pancreatic cancers that had not responded to standard treatments. The drug is designed to target and kill cancer cells. The study aimed to find a …
Phase: PHASE1 • Sponsor: Seagen, a wholly owned subsidiary of Pfizer • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
Targeted radiation zaps Hard-to-Treat cancers in early trial
Disease control TerminatedThis early-stage trial tests a new drug, [177Lu]Lu-EVS459, that delivers radiation directly to cancer cells in people with advanced ovarian or lung cancers. The study aims to see if the treatment is safe and tolerable, and to get an early look at whether it can shrink tumors. Par…
Phase: PHASE1 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
New cancer drug debio 0123 tested in early trial
Disease control TerminatedThis early-stage study tested a new drug called Debio 0123 in 66 adults with advanced solid tumors that had stopped responding to standard treatments. The main goals were to find the safest dose and to check for side effects and any signs that the drug could shrink tumors. The st…
Phase: PHASE1 • Sponsor: Debiopharm International SA • Aim: Disease control
Last updated Jun 27, 2026 14:01 UTC
-
New drug targets Hard-to-Treat tumors in early trial
Disease control TerminatedThis study tested a drug called bemarituzumab in 260 adults with solid tumors that have high levels of a protein called FGFR2b. The main goals were to see if the drug is safe and if it can shrink tumors. Participants had already tried other treatments without success.
Phase: PHASE1, PHASE2 • Sponsor: Amgen • Aim: Disease control
Last updated Jun 27, 2026 14:01 UTC
-
Antibiotics at home after early water break: study stopped early
Disease control TerminatedThis study looked at whether giving pregnant people oral antibiotics at home could delay delivery after their water broke very early (between 18 and 23 weeks). The goal was to see if more people would stay pregnant for at least 28 days after the water broke. The study was stopped…
Phase: PHASE4 • Sponsor: University Hospitals Cleveland Medical Center • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
Ovarian cancer combo trial halted early
Disease control TerminatedThis study tested a new drug, CRLX101, combined with standard chemotherapy (paclitaxel) in 30 women with ovarian cancer that came back or didn't go away. The goal was to find the safest dose and see if the combination helped shrink tumors. The trial was terminated early, so resul…
Phase: PHASE1, PHASE2 • Sponsor: NewLink Genetics Corporation • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
Liver transplants for HIV-HCV patients: a feasibility study
Disease control TerminatedThis study aimed to see if liver transplantation is possible and safe for people infected with both HIV and hepatitis C. Fifteen patients were enrolled to track survival, virus behavior, and drug interactions after transplant. The goal was to understand how these two viruses inte…
Phase: PHASE2 • Sponsor: ANRS, Emerging Infectious Diseases • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
Robot vs. vaginal surgery for prolapse: which is better? trial stopped early.
Disease control TerminatedThis study compared two surgical repairs for pelvic organ prolapse (when organs like the bladder or uterus drop into the vagina). One method uses a robot to place mesh inside the abdomen; the other uses stitches through the vagina to tighten natural ligaments. The trial enrolled …
Phase: NA • Sponsor: Loma Linda University • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New cancer drug BBI-355 trial halted early – what we know
Disease control TerminatedThis early-phase trial tested a new oral drug called BBI-355, alone or with other targeted therapies, in people with advanced solid tumors that had extra DNA (oncogene amplifications). The study aimed to find the safest dose and check for side effects. It was terminated early, so…
Phase: PHASE1 • Sponsor: Boundless Bio, Inc. • Aim: Disease control
Last updated Jun 27, 2026 13:04 UTC
-
HIV drug showdown: which strategy works best for new patients?
Disease control TerminatedThis study compared two HIV treatment approaches in people who had never taken HIV drugs before. One group started with a three-drug combo for 16 weeks, then switched to a two-drug combo. The other group took a two-drug combo from the start. The goal was to see if the first appro…
Phase: PHASE3 • Sponsor: ANRS, Emerging Infectious Diseases • Aim: Disease control
Last updated Jun 27, 2026 13:04 UTC
-
Experimental cancer drug trial halted early
Disease control TerminatedThis early-stage study tested a new drug called PF-07265807 in people with advanced or metastatic solid tumors that had spread. The main goals were to find a safe dose and check for side effects. The trial was terminated early, so results are limited.
Phase: PHASE1 • Sponsor: Pfizer • Aim: Disease control
Last updated Jun 27, 2026 13:04 UTC
-
Weight loss and hormone pill tested for fertility-sparing cancer treatment – but trial stopped early
Disease control TerminatedThis study tested whether combining weight management (diet and exercise guidance) with a daily hormone pill (megestrol acetate) could help obese patients with early-stage endometrial cancer who want to preserve their fertility. The goal was to see if the cancer would completely …
Phase: PHASE2, PHASE3 • Sponsor: Xiaojun Chen • Aim: Disease control
Last updated Jun 27, 2026 13:03 UTC
-
Cancer combo trial halted early after enrolling only 5 patients
Disease control TerminatedThis study tested a new drug (INCB099280) combined with a standard cancer drug (axitinib) in adults with advanced solid tumors that had stopped responding to other treatments. The main goals were to check safety and see if the combination could shrink tumors. The trial was termin…
Phase: PHASE1, PHASE2 • Sponsor: Incyte Corporation • Aim: Disease control
Last updated Jun 27, 2026 13:03 UTC
-
Ovarian cancer drug combo trial halted early
Disease control TerminatedThis phase 3 trial tested a combination of two targeted drugs, alpelisib and olaparib, against standard chemotherapy in 358 women with a tough-to-treat type of ovarian cancer that had stopped responding to platinum-based chemotherapy. The study only included women without a BRCA …
Phase: PHASE3 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 13:03 UTC
-
New cancer drug trial halted early – what we know
Disease control TerminatedThis early-phase trial tested a new drug called PRO1107 in 33 people with advanced solid tumors, including ovarian, endometrial, breast, lung, and other cancers. The study aimed to check safety and see if the drug could shrink tumors. However, the trial was terminated early, so f…
Phase: PHASE1, PHASE2 • Sponsor: Genmab • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
Cancer drug combo tested for rare gene mutation – but trial stopped early
Disease control TerminatedThis study tested two drugs, niraparib and bevacizumab, alone or together, in people with recurrent endometrial or ovarian cancer that has a specific gene change called ARID1A. The goal was to see if the drugs could shrink tumors. However, the trial was stopped early after enroll…
Phase: PHASE2 • Sponsor: University of Oklahoma • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
Engineered virus takes on cancer in first human trial
Disease control TerminatedThis early-phase trial tested ASP1012, a virus engineered to infect and kill cancer cells while making them visible to the immune system. It was given alone or with the immunotherapy pembrolizumab to 15 adults with advanced solid tumors. The main goals were to check safety and fi…
Phase: PHASE1 • Sponsor: Astellas Pharma Global Development, Inc. • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
HIV drug switch may boost heart health and trim body fat
Disease control TerminatedThis study looked at whether switching from a standard HIV drug combination to a different one (Delstrigo) could improve cholesterol, body fat, and blood sugar in people with HIV. The study planned to enroll 60 adults whose HIV was already well-controlled. Participants were rando…
Phase: PHASE4 • Sponsor: Chelsea and Westminster NHS Foundation Trust • Aim: Disease control
Last updated Jun 27, 2026 12:39 UTC
-
Can early speech therapy boost language in preterm babies?
Disease control TerminatedThis study tested an early speech therapy program for children born very prematurely or with severe growth restriction. The program involved 10 to 20 sessions with a trained speech therapist from 6 to 24 months of age. The goal was to see if it could reduce language and communica…
Phase: NA • Sponsor: Centre Hospitalier Sud Francilien • Aim: Disease control
Last updated Jun 27, 2026 12:38 UTC
-
Immune booster added to standard cervical cancer treatment shows promise in early trial
Disease control TerminatedThis study tested adding the immune-boosting drug pembrolizumab to standard chemoradiation for people with advanced cervical cancer. The goal was to see if the combination is safe and to find the best dose. Only one person was enrolled before the study was stopped early, so resul…
Phase: PHASE1 • Sponsor: Royal Marsden NHS Foundation Trust • Aim: Disease control
Last updated Jun 27, 2026 12:36 UTC
-
Can a daily injection reshape bodies of HIV patients?
Disease control TerminatedThis study looked at whether tesamorelin (Egrifta), a daily injection that boosts growth hormone, can improve body composition in people with HIV who have excess belly fat (lipodystrophy). Six participants received the drug for up to 12 months, with researchers measuring liver fa…
Phase: PHASE4 • Sponsor: Columbia University • Aim: Disease control
Last updated Jun 27, 2026 12:36 UTC
-
Experimental cell therapy targets tough cancers, but trial ends early
Disease control TerminatedThis early-phase trial tested a new approach: taking a patient's own white blood cells, genetically modifying them in the lab to recognize a specific cancer mutation (KRAS G12D), and infusing them back to attack tumors. The study enrolled only 5 adults with advanced gastrointesti…
Phase: PHASE1, PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 12:35 UTC
-
Promising combo trial for prostate cancer halted early
Disease control TerminatedThis study tested a combination of two drugs—tivozanib and enzalutamide—in men with advanced prostate cancer that had stopped responding to standard hormone therapy. Enzalutamide blocks male hormones that fuel cancer growth, while tivozanib cuts off the tumor's blood supply. The …
Phase: PHASE2 • Sponsor: Massachusetts General Hospital • Aim: Disease control
Last updated Jun 27, 2026 12:35 UTC
-
Cancer drug niraparib tested before prostate surgery – early trial stopped
Disease control TerminatedThis phase II trial tested the drug niraparib (Zejula) in 11 men with high-risk prostate cancer that had not spread. All men had specific DNA repair gene mutations. They took niraparib before having their prostate removed surgically. The goal was to see if the drug could eliminat…
Phase: PHASE2 • Sponsor: University of California, Davis • Aim: Disease control
Last updated Jun 27, 2026 12:33 UTC
-
Experimental combo for tough prostate cancer shows early promise but trial halted
Disease control TerminatedThis study tested a combination of two drugs, bortezomib and docetaxel, in 15 men with advanced prostate cancer that had stopped responding to hormone therapy. The goal was to see if the combo could lower PSA levels and ease pain. The trial was terminated early, so the findings a…
Phase: PHASE2 • Sponsor: University of Southern California • Aim: Disease control
Last updated Jun 27, 2026 12:33 UTC
-
New cocktail of cancer drugs tested in desperate cases
Disease control TerminatedThis early-phase trial tested combinations of the drugs bevacizumab and temsirolimus, sometimes with valproic acid or cetuximab, in 154 people with advanced cancers or certain non-cancerous but progressive diseases. The main goal was to find safe doses and look for any signs that…
Phase: PHASE1 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 12:32 UTC
-
New prostate cancer combo trial ends early
Disease control TerminatedThis study tested a new drug called exicorilant (CORT125281) combined with enzalutamide in men with metastatic castration-resistant prostate cancer. The goal was to find a safe dose and check for side effects. The trial was terminated early, so results are limited. It involved 39…
Phase: PHASE1, PHASE2 • Sponsor: Corcept Therapeutics • Aim: Disease control
Last updated Jun 27, 2026 12:32 UTC
-
Continued EryDex treatment studied in rare neurological disorder
Disease control TerminatedThis study offered continued treatment with EryDex to 101 people with ataxia telangiectasia (A-T) who had finished a previous trial. The main goal was to monitor safety, including side effects and serious events. The study was terminated early, and it did not aim to cure the dise…
Phase: PHASE3 • Sponsor: Quince Therapeutics S.p.A. • Aim: Disease control
Last updated Jun 27, 2026 12:29 UTC
-
Cancer drug cabozantinib tested in tough prostate cancers
Disease control TerminatedThis phase 2 trial tested the drug cabozantinib in men with a hard-to-treat type of prostate cancer that had spread and stopped responding to hormone therapy. The study focused on patients whose tumors had specific genetic changes or had spread to the liver. Only 4 men were enrol…
Phase: PHASE2 • Sponsor: Weill Medical College of Cornell University • Aim: Disease control
Last updated Jun 27, 2026 12:28 UTC
-
Diet and drug combo aim to tame tumor side effects
Disease control TerminatedThis study tested a new drug called serabelisib combined with a diet that lowers insulin levels, with or without another chemotherapy drug, in people with advanced solid tumors that have a specific genetic change (PIK3CA mutation). The goal was to see if the diet could reduce sid…
Phase: PHASE1 • Sponsor: Faeth Therapeutics • Aim: Disease control
Last updated Jun 27, 2026 12:26 UTC
-
Tailored cancer therapy put to the test
Disease control TerminatedThis study tested a precision medicine approach for people with advanced cancers like breast, ovarian, pancreatic, prostate, or sarcoma. Researchers used genetic and protein tests to track how the cancer changes and then a team of experts recommended personalized drugs. The goal …
Phase: PHASE2 • Sponsor: OHSU Knight Cancer Institute • Aim: Disease control
Last updated Jun 27, 2026 12:25 UTC
-
Experimental TIL therapy for advanced gynecological tumors shows early promise but study halted
Disease control TerminatedThis early study tested a new treatment called GT201 for people with advanced gynecological tumors, like advanced cervical cancer. The treatment uses a patient's own immune cells (tumor-infiltrating lymphocytes) to fight the cancer. The study was terminated early after enrolling …
Phase: NA • Sponsor: Grit Biotechnology • Aim: Disease control
Last updated Jun 27, 2026 12:24 UTC
-
Experimental TIL therapy tested in one patient for advanced gynecological tumors
Disease control TerminatedThis early-phase study tested an experimental cell therapy called GT201, made from a patient's own immune cells, for advanced gynecological tumors. Only one person took part before the study was stopped early. The goal was to check safety and see if the treatment could shrink tum…
Phase: EARLY_PHASE1 • Sponsor: Grit Biotechnology • Aim: Disease control
Last updated Jun 27, 2026 12:24 UTC
-
Cancer drug combo trial halted early after only 13 patients
Disease control TerminatedThis study tested a drug called zenocutuzumab combined with other medicines in people with two types of cancer: non-small cell lung cancer with a specific gene change (NRG1 fusion) and advanced prostate cancer that no longer responds to hormone therapy. The goal was to see if the…
Phase: PHASE2 • Sponsor: Partner Therapeutics, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:24 UTC
-
Common diabetes and acne drugs tested against cancer
Disease control TerminatedThis phase 2 trial tested whether combining metformin (a diabetes drug) with doxycycline (an antibiotic) could help treat localized breast and uterine cancers. The study enrolled 29 people who were scheduled for surgery. Researchers looked at changes in certain proteins in the tu…
Phase: PHASE2 • Sponsor: Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
Promising combo for prostate cancer halted early
Disease control TerminatedThis study looked at adding ribociclib to the standard hormone therapy enzalutamide for men with a certain type of advanced prostate cancer that had spread and no longer responded to hormone therapy alone. The goal was to find the best dose and see if the combination could lower …
Phase: PHASE1, PHASE2 • Sponsor: Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
New cancer drug AUR109 tested in three tumor types – trial halted early
Disease control TerminatedThis phase 2 study tested three doses of the experimental drug AUR109 in 29 adults with advanced colorectal, ovarian, or kidney cancer who had already tried at least two other treatments. The goal was to see if the drug could shrink tumors and to check its safety. The trial was t…
Phase: PHASE2 • Sponsor: Aurigene Discovery Technologies Limited • Aim: Disease control
Last updated Jun 27, 2026 12:09 UTC
-
Pazopanib dose hunt in frail seniors halted early
Disease control TerminatedThis phase 1 study tested the cancer drug pazopanib in 18 frail elderly patients (aged 75+) with metastatic cancers like kidney, lung, or breast cancer. The goal was to find the highest safe dose by starting at 400 mg daily and increasing if tolerated. The study was terminated ea…
Phase: PHASE1 • Sponsor: Institut Claudius Regaud • Aim: Disease control
Last updated Jun 27, 2026 12:08 UTC
-
Experimental immune cell therapy targets Hard-to-Treat cancers
Disease control TerminatedThis early-phase trial tested a personalized cell therapy called ITIL-306 in people with advanced ovarian, lung, or kidney cancers that had not responded to standard treatments. The therapy uses a patient's own immune cells (TILs) taken from their tumor, modified to better attack…
Phase: PHASE1 • Sponsor: Instil Bio • Aim: Disease control
Last updated Jun 27, 2026 12:08 UTC
-
Weekly HIV pill shows promise but study halted early
Disease control TerminatedThis study tested whether a once-weekly oral combination of two experimental drugs (lepetegravir and lenacapavir pacfosacil) could control HIV as well as the standard daily pill Biktarvy. It enrolled 73 people newly diagnosed with HIV-1 who had never taken HIV medication. The stu…
Phase: PHASE2, PHASE3 • Sponsor: Gilead Sciences • Aim: Disease control
Last updated Jun 27, 2026 12:07 UTC
-
New hope for advanced cervical cancer: targeted drug combo shows promise
Disease control TerminatedThis trial tested a drug called tisotumab vedotin, alone or with other medicines, in people with cervical cancer that had come back or spread. The study included 214 participants and aimed to find the best dose and see if the tumors shrank. The trial was stopped early, but the re…
Phase: PHASE1, PHASE2 • Sponsor: Seagen, a wholly owned subsidiary of Pfizer • Aim: Disease control
Last updated Jun 27, 2026 12:07 UTC
-
Experimental cancer drug GEN1047 tested in humans – study halted early
Disease control TerminatedThis study tested a new drug called GEN1047 in people with advanced solid tumors (breast, endometrial, ovarian, or lung cancer) who had no other treatment options. The goal was to check safety, side effects, and how the body processes the drug. The study was terminated early, but…
Phase: PHASE1, PHASE2 • Sponsor: Genmab • Aim: Disease control
Last updated Jun 27, 2026 12:07 UTC
-
Promising prostate cancer combo trial stalls after just 7 patients
Disease control TerminatedThis phase II trial tested two drugs—denosumab and enzalutamide—together in men with advanced prostate cancer that no longer responds to hormone therapy and has spread to the bones. The goal was to see if the combination could slow cancer growth better than enzalutamide alone. Ho…
Phase: PHASE2 • Sponsor: Cancer Trials Ireland • Aim: Disease control
Last updated Jun 27, 2026 12:06 UTC
-
Hormone pill tested for prostate troubles – but trial halted early
Disease control TerminatedThis phase 2 trial tested a hormone drug called etonogestrel (Org 3236) in 16 men with moderate to severe urinary symptoms from an enlarged prostate. The goal was to see if the drug could shrink the prostate, improve urine flow, and boost quality of life compared to a placebo. Ho…
Phase: PHASE2 • Sponsor: Organon and Co • Aim: Disease control
Last updated Jun 27, 2026 12:05 UTC
-
Cancer combo trial ends before it begins: only one patient enrolled
Disease control TerminatedThis early-phase trial aimed to test the safety of combining two drugs, adagrasib and olaparib, in people with advanced solid tumors that have a specific genetic change called KRAS G12C. The study planned to include patients with certain breast, ovarian, pancreatic, and lung canc…
Phase: PHASE1 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 12:05 UTC
-
Hormone therapy and HIV drugs: a delicate balance for transgender women
Disease control TerminatedThis study looked at how feminizing hormone therapy (estradiol) interacts with HIV medications in transgender women living with HIV. It included 93 participants who were already on HIV treatment and gave them standardized estradiol doses for up to 48 weeks. The goal was to see if…
Phase: PHASE2 • Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) • Aim: Disease control
Last updated Jun 27, 2026 12:05 UTC
-
BioNTech's RNA cancer therapy trial halted early
Disease control TerminatedThis study tested an experimental RNA-based therapy called BNT142 in people with advanced solid tumors that have a specific protein called CLDN6. The goal was to see if it was safe and could shrink tumors. However, the trial was terminated early, so we don't have clear answers ab…
Phase: PHASE1, PHASE2 • Sponsor: BioNTech SE • Aim: Disease control
Last updated Jun 27, 2026 12:05 UTC
-
New drug cocktail tested for ovarian cancer maintenance
Disease control TerminatedThis study looked at whether adding a third drug (fluzoparib) to a two-drug combination (apatinib and letrozole) could help control recurrent ovarian cancer longer. It included people with a specific type of ovarian cancer that had come back but still responded to platinum chemot…
Phase: NA • Sponsor: Peking Union Medical College Hospital • Aim: Disease control
Last updated Jun 27, 2026 12:05 UTC
-
HIV and opioid treatment study halted early – what we know
Disease control TerminatedThis study looked at whether different medications for opioid use disorder (methadone, buprenorphine/naloxone, or naltrexone) could reduce immune system inflammation in people with HIV. Researchers measured changes in blood markers of immune activation over 24 weeks. The trial wa…
Phase: PHASE2 • Sponsor: University of Pennsylvania • Aim: Disease control
Last updated Jun 27, 2026 12:04 UTC
-
HIV pill combo fails to slim belly fat in early trial
Disease control TerminatedThis study tested whether switching to a two-drug HIV treatment (raltegravir plus maraviroc) could reduce belly fat (lipohypertrophy) in people whose HIV was already well-controlled. It included 48 adults on stable HIV therapy for at least 5 years. The study was stopped early, so…
Phase: PHASE2 • Sponsor: ANRS, Emerging Infectious Diseases • Aim: Disease control
Last updated Jun 27, 2026 12:04 UTC
-
Promising prostate cancer combo study halted early
Disease control TerminatedThis study tested whether adding the drug SHR3680 to standard hormone therapy could improve outcomes for men with high-risk prostate cancer before they had surgery to remove the prostate. The trial enrolled 391 participants and aimed to see if the combination could eliminate all …
Phase: PHASE3 • Sponsor: Jiangsu HengRui Medicine Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 12:03 UTC
-
Growth hormone study for short kids halted early
Disease control TerminatedThis study looked at two ways of giving growth hormone to short children who were born small for their age. The goal was to see which dosing method works better for growth and has fewer side effects on metabolism. Only 10 children took part before the study was stopped early.
Phase: PHASE4 • Sponsor: Assistance Publique - Hôpitaux de Paris • Aim: Disease control
Last updated Jun 27, 2026 12:03 UTC
-
Experimental cancer drug CPO-100 trial halted early
Disease control TerminatedThis early-stage study tested a new drug called CPO-100 in 34 adults with advanced solid tumors that had not responded to at least two prior treatments. The goal was to check safety and find the right dose. The study was terminated early, so results are limited.
Phase: PHASE1 • Sponsor: Conjupro Biotherapeutics, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:03 UTC
-
New IVF drug trial halted early: did it help embryo growth?
Disease control TerminatedThis early-stage trial tested whether adding the drug FE999302 to standard IVF hormones could increase the number of high-quality embryos in women undergoing fertility treatment. The study enrolled 310 women aged 18–40 with specific hormone levels. The trial was terminated early,…
Phase: PHASE1 • Sponsor: Ferring Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 12:02 UTC
-
Timing of fertility drug may affect egg quality in IVF
Disease control TerminatedThis early-phase study looked at whether giving an extra fertility drug (FE 999302) at different times during ovarian stimulation could improve the number of good-quality embryos in women undergoing IVF. The trial included 106 women with high ovarian reserve and was stopped early…
Phase: PHASE1 • Sponsor: Ferring Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 12:02 UTC
-
Experimental prostate cancer pill put to the test
Disease control TerminatedThis early-stage study tested a new drug called TQB3720 in 192 men with advanced prostate cancer that had stopped responding to hormone therapy. The main goal was to find a safe dose and see how the drug moves through the body. The study was stopped early, so results are limited.
Phase: PHASE1 • Sponsor: Chia Tai Tianqing Pharmaceutical Group Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 12:01 UTC
-
Cancer drug combo trial halted after only 9 patients
Disease control TerminatedThis study tested a combination of two drugs, futibatinib and pembrolizumab, in people with a specific type of advanced endometrial cancer that had spread and was not responding to standard treatments. The goal was to see if the combination could shrink tumors and provide lasting…
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 12:01 UTC
-
Experimental cancer combo shows early promise but study halted
Disease control TerminatedThis early-phase trial tested a new drug called nanrilkefusp alfa, which helps activate immune cells, both alone and combined with the immunotherapy pembrolizumab. It included 115 people with various advanced solid tumors that had stopped responding to standard treatments. The st…
Phase: PHASE1 • Sponsor: SOTIO Biotech AG • Aim: Disease control
Last updated Jun 27, 2026 12:01 UTC
-
Immunotherapy combo shows promise for advanced cervical cancer
Disease control TerminatedThis phase 2 trial tested two immunotherapy drugs, AGEN2034 and AGEN1884, in 211 women with recurrent cervical cancer that had progressed after chemotherapy. One group received AGEN2034 alone, the other received both drugs. The goal was to see if the tumors shrank. The study was …
Phase: PHASE2 • Sponsor: Agenus Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:01 UTC
-
Experimental drug shows promise for rare genetic disorder
Disease control TerminatedThis Phase II trial tested a drug called N-Acetyl-L-Leucine (IB1001) in 17 people with Ataxia-Telangiectasia, a rare genetic disease that affects movement and immunity. The study aimed to see if the drug could improve symptoms and slow the disease over time. The trial was termina…
Phase: PHASE2 • Sponsor: IntraBio Inc • Aim: Disease control
Last updated Jun 27, 2026 12:00 UTC
-
Immune cell therapy tested for tough childhood cancers
Disease control TerminatedThis early-phase study tested a treatment using donated natural killer (NK) cells from cord blood, combined with chemotherapy, for children and young adults with solid tumors that returned or didn't respond to standard care. The goal was to find the safest dose and check for side…
Phase: PHASE1 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 11:03 UTC
-
Balloon shield for prostate radiation: a failed promise?
Disease control TerminatedThis study tested a temporary biodegradable balloon placed between the prostate and rectum during radiation therapy for intermediate-risk prostate cancer. The goal was to see if the balloon could reduce radiation damage to the rectum by pushing it away from the prostate. The stud…
Phase: NA • Sponsor: Centre Oscar Lambret • Aim: Disease control
Last updated Jun 27, 2026 11:03 UTC
-
New chemo combo after radiation shows promise for advanced cervical cancer
Disease control TerminatedThis study looked at whether adding a specific chemotherapy combination (carboplatin and paclitaxel) after standard chemoradiation could help people with advanced cervical cancer that has spread to lymph nodes near the kidneys. The trial planned to enroll 21 participants but was …
Phase: PHASE2 • Sponsor: Centre Oscar Lambret • Aim: Disease control
Last updated Jun 27, 2026 11:03 UTC
-
New drug combo tested for Tough-to-Treat prostate cancer
Disease control TerminatedThis study tested a combination of two drugs, apalutamide and abiraterone, along with prednisone, in men whose prostate cancer had spread and stopped responding to standard hormone therapy. The goal was to see if this combination could slow cancer growth. Only 7 men took part bef…
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 11:01 UTC
-
Promising combo therapy for aggressive prostate cancer tested before surgery
Disease control TerminatedThis study tested whether giving a targeted radiation drug (LuPSMA) with or without an immunotherapy drug (ipilimumab) before prostate removal surgery is safe and feasible for men with very high-risk prostate cancer. Only one participant was enrolled before the study was stopped …
Phase: PHASE1, PHASE2 • Sponsor: University Hospital, Essen • Aim: Disease control
Last updated Jun 27, 2026 11:01 UTC
-
Promising combo for cervical cancer hits roadblock: trial ends early
Disease control TerminatedThis phase 2 trial tested a new treatment sequence for stage IB2 to IVA cervical cancer. Patients received a combination of gemcitabine and cisplatin chemotherapy along with radiation, followed by more gemcitabine. The goal was to see if this approach could improve progression-fr…
Phase: PHASE2 • Sponsor: Centre Oscar Lambret • Aim: Disease control
Last updated Jun 27, 2026 11:00 UTC
-
Deep endometriosis: surgery vs. IVF in fertility showdown
Disease control TerminatedThis study compared two approaches for women with deep endometriosis who want to get pregnant: surgery to remove endometriosis or fertility treatment (IVF). Researchers planned to track pregnancy and live birth rates. The trial was stopped early after enrolling 38 women, so the r…
Phase: NA • Sponsor: Horsens Hospital • Aim: Disease control
Last updated Jun 27, 2026 11:00 UTC
-
New drug combo for cervical cancer shows early promise, but trial halted
Disease control TerminatedThis early-phase trial tested a combination of two drugs—toripalimab (an immunotherapy) and chidamide (a targeted therapy)—in women with advanced cervical cancer that had spread or returned. Only 5 participants were enrolled before the study was terminated. The goal was to see if…
Phase: PHASE1, PHASE2 • Sponsor: Sun Yat-sen University • Aim: Disease control
Last updated Jun 27, 2026 11:00 UTC
-
Promising combo for prostate cancer falls short: trial ends early
Disease control TerminatedThis study tested a new drug, tazemetostat, combined with standard hormone therapies (enzalutamide or abiraterone/prednisone) in men with advanced prostate cancer that no longer responds to hormone therapy alone. The goal was to see if the combination could slow cancer growth bet…
Phase: PHASE1, PHASE2 • Sponsor: Epizyme, Inc. • Aim: Disease control
Last updated Jun 27, 2026 11:00 UTC
-
Grape seed extract and diabetes drug tested for prostate cancer side effects
Disease control TerminatedThis study looked at whether a grape seed extract called OPC or the diabetes drug metformin could lower levels of AGEs (advanced glycation endproducts) in men with prostate cancer who are on hormone therapy. The trial planned to enroll 41 participants but was terminated early. Th…
Phase: PHASE2 • Sponsor: Medical University of South Carolina • Aim: Disease control
Last updated Jun 27, 2026 09:11 UTC
-
Experimental cancer drug DCC-3084 tested in early trial
Disease control TerminatedThis early-phase trial tested an oral drug called DCC-3084, alone or with other cancer treatments, in 29 people with advanced solid tumors that have MAPK pathway mutations (like certain lung, pancreatic, or skin cancers). The study aimed to find safe doses and see if tumors shrin…
Phase: PHASE1 • Sponsor: Deciphera Pharmaceuticals, LLC • Aim: Disease control
Last updated Jun 27, 2026 09:10 UTC
-
New MRI-Guided radiation aims to cut prostate cancer treatment time
Disease control TerminatedThis phase 2 trial tested whether MRI-guided radiation therapy, given in fewer but higher doses, could safely treat high-risk prostate cancer while reducing side effects. The study enrolled 6 men with localized, high-risk prostate cancer who also received standard hormone therapy…
Phase: PHASE2 • Sponsor: Thomas Jefferson University • Aim: Disease control
Last updated Jun 27, 2026 09:09 UTC
-
Quit smoking before surgery to cut complications, study finds
Disease control TerminatedThis study looked at whether a structured smoking cessation program starting four weeks before surgery could reduce complications in smokers undergoing intermediate to high-risk operations. Researchers planned to enroll 251 adult smokers scheduled for surgeries like abdominal, th…
Phase: NA • Sponsor: Luzerner Kantonsspital • Aim: Disease control
Last updated Jun 27, 2026 09:09 UTC
-
New pill for Hard-to-Treat cancers shows early promise in small study
Disease control TerminatedThis early-stage study tested a new oral drug, ATX-559, in 17 people with advanced solid tumors that had stopped responding to standard treatments. The main goal was to find a safe dose and check for side effects. The study was terminated early, so results are limited.
Phase: PHASE1 • Sponsor: Accent Therapeutics • Aim: Disease control
Last updated Jun 27, 2026 09:08 UTC
-
New cancer drug shows early promise, but trial cut short
Disease control TerminatedThis early-stage study tested a new drug called PF-07826390, given alone or with another drug (sasanlimab), in people with advanced solid tumors like lung, kidney, and colorectal cancers. The goal was to check safety and find the right dose. Only 10 people took part, and the stud…
Phase: PHASE1 • Sponsor: Pfizer • Aim: Disease control
Last updated Jun 27, 2026 09:08 UTC
-
New syphilis combo treatment tested in HIV patients – trial cut short
Disease control TerminatedThis study looked at two different antibiotic combinations for treating early syphilis in people living with HIV. One group received a single shot of ceftriaxone plus a week of doxycycline pills, while the other got the standard single shot of penicillin plus the same doxycycline…
Phase: PHASE4 • Sponsor: National Taiwan University Hospital • Aim: Disease control
Last updated Jun 27, 2026 09:08 UTC
-
Engineered immune cells take aim at Hard-to-Treat prostate cancer
Disease control TerminatedThis early-stage study tested a new treatment called BPX-601 for people with advanced prostate cancer that had stopped responding to other therapies. The treatment uses a patient's own immune cells, modified to recognize and attack cancer cells carrying a specific marker (PSCA). …
Phase: PHASE1 • Sponsor: Regeneron Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 09:07 UTC
-
Laser zaps prostate tumors in tiny study
Disease control TerminatedThis study tested a new way to treat prostate cancer using a laser guided by MRI images. Only 2 men took part before the study was stopped. The goal was to see if the treatment was safe and could precisely target cancer while avoiding healthy tissue.
Phase: NA • Sponsor: Jonsson Comprehensive Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 09:07 UTC
-
Promising prostate cancer treatment trial halted early
Disease control TerminatedThis phase 3 study tested a radioactive antibody called 177Lu-DOTA-rosopatamab combined with standard care for men with metastatic castration-resistant prostate cancer that had progressed after hormone therapy. The goal was to see if the combination slowed cancer growth or improv…
Phase: PHASE3 • Sponsor: Telix Pharmaceuticals (Innovations) Pty Ltd • Aim: Disease control
Last updated Jun 27, 2026 09:07 UTC
-
Cervical lesion drug trial halted early
Disease control TerminatedThis study tested a vaginal insert called ABI-2280 in women with cervical precancerous lesions (CIN). The goal was to see if it was safe and could help clear the abnormal cells. The trial was stopped early, so we don't have full results. It involved 44 women aged 25-55 who used t…
Phase: PHASE1, PHASE2 • Sponsor: Antiva Biosciences • Aim: Disease control
Last updated Jun 27, 2026 09:06 UTC
-
Can texts and peers help trans women beat HIV? trial cut short
Disease control TerminatedThis study aimed to find the best way to help transgender women living with HIV reach undetectable viral levels. Participants received either text messages, help from a peer health navigator, or both. The trial was ended early, so results are limited.
Phase: NA • Sponsor: Friends Research Institute, Inc. • Aim: Disease control
Last updated Jun 27, 2026 09:04 UTC
-
Experimental drug targets Hard-to-Treat cancers, but trial ends early
Disease control TerminatedThis study tested an experimental drug called vobramitamab duocarmazine in people with advanced prostate cancer and other solid tumors that stopped responding to standard treatments. The goal was to see if the drug could shrink tumors or slow cancer growth. The trial was terminat…
Phase: PHASE2 • Sponsor: MacroGenics • Aim: Disease control
Last updated Jun 27, 2026 09:04 UTC
-
Experimental drug shows promise for Hard-to-Treat prostate cancer
Disease control TerminatedThis phase 2 study tested the drug erdafitinib in 11 men with castration-resistant prostate cancer that had spread to the bone. The goal was to see if the drug could slow the cancer and to study bone and blood markers. The trial was terminated early, so results are limited.
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 09:02 UTC
-
Promising prostate device trial halted after just one patient
Disease control TerminatedThis study tested a new device that uses water electrolysis to shrink prostate tissue and relieve urinary symptoms in men with benign prostatic hyperplasia (BPH). The goal was to see if it could improve symptoms by at least 30% and be safe. However, the trial was terminated early…
Phase: NA • Sponsor: ProstaCare Pty Ltd • Aim: Disease control
Last updated Jun 27, 2026 09:01 UTC
-
Ovarian cancer drug combo trial halted early – what we know
Disease control TerminatedThis study tested a new drug combination (SON-1010 plus atezolizumab) in people with advanced solid tumors, especially platinum-resistant ovarian cancer. The goal was to see if the combination was safe and could slow tumor growth. The trial was terminated early, so results are li…
Phase: PHASE1, PHASE2 • Sponsor: Sonnet BioTherapeutics • Aim: Disease control
Last updated Jun 27, 2026 09:01 UTC
-
New cancer drug tested in people with advanced tumors
Disease control TerminatedThis early study tested a new drug called PHN-010 in 26 people with advanced cancers like lung, colon, and ovarian cancer. The drug is designed to deliver a powerful treatment directly to cancer cells. The main goals were to check safety and find the right dose, but the study was…
Phase: PHASE1 • Sponsor: Pheon Therapeutics • Aim: Disease control
Last updated Jun 27, 2026 09:00 UTC
-
New combo treatment targets returned prostate cancer
Disease control TerminatedThis study tested a treatment for prostate cancer that came back after previous radiation. It combined temporary radioactive implants placed in the prostate, daily external radiation to the pelvis for 5 weeks, and 6 months of hormone therapy. The goal was to see if this approach …
Phase: PHASE1, PHASE2 • Sponsor: Loyola University • Aim: Disease control
Last updated Jun 27, 2026 09:00 UTC
-
Experimental drug shows promise for recurrent gynecologic cancers
Disease control TerminatedThis study tested a drug called sacituzumab govitecan in people with ovarian, endometrial, or cervical cancer that returned after at least two rounds of standard treatment. The goal was to see if the drug could shrink or eliminate tumors. The study was terminated early with only …
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 08:13 UTC
-
HIV cancer hope: immune combo shows early promise but trial halted
Disease control TerminatedThis early-phase trial tested two immunotherapy drugs, ipilimumab and nivolumab, in people with HIV who had advanced solid tumors or Hodgkin lymphoma that had spread or come back. The goal was to find the safest dose and see if the combination could shrink tumors. The study was t…
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 08:13 UTC
-
Experimental cell therapy for cervical cancer stalls after just 5 patients
Disease control TerminatedThis early-phase trial tested a new treatment called TC-E202 for people with advanced cervical cancer that had stopped responding to standard treatments. TC-E202 uses a patient's own immune cells, which are genetically modified in a lab to better recognize and attack cancer cells…
Phase: PHASE1, PHASE2 • Sponsor: TCRCure Biopharma Ltd. • Aim: Disease control
Last updated Jun 27, 2026 08:12 UTC
-
New drug combo for Hard-to-Treat cancers shows early promise but trial halted
Disease control TerminatedThis early-stage trial tested a new drug called RP-3467, alone or with olaparib, in 26 adults with advanced solid tumors that had stopped responding to standard treatments. The main goal was to check safety and find the right dose. The study was terminated, so full results are no…
Phase: PHASE1 • Sponsor: Repare Therapeutics • Aim: Disease control
Last updated Jun 27, 2026 08:11 UTC
-
New cancer drug OC-001 tested in advanced tumors – trial ends early
Disease control TerminatedThis early-phase trial tested an experimental drug called OC-001, given alone or with the immunotherapy avelumab, in 73 people with various advanced or metastatic cancers (like lung, breast, and bladder cancer). The main goals were to check safety and how the drug moves through t…
Phase: PHASE1, PHASE2 • Sponsor: Ocellaris Pharma, Inc. • Aim: Disease control
Last updated Jun 27, 2026 08:11 UTC
-
New cancer drug trial halted early – what we know
Disease control TerminatedThis study tested a new drug, felmetatug vedotin, alone or with pembrolizumab, in people with advanced solid tumors like ovarian, breast, and lung cancer. The goal was to check safety and find the right dose. The trial was terminated early, so results are limited.
Phase: PHASE1 • Sponsor: Seagen, a wholly owned subsidiary of Pfizer • Aim: Disease control
Last updated Jun 27, 2026 08:09 UTC
-
Immune cells supercharged to fight ovarian cancer
Disease control TerminatedThis early-stage study tested a new way to treat ovarian, fallopian tube, or primary peritoneal cancer that had returned or stopped responding to standard treatments. Researchers took a type of white blood cell (monocytes) from each participant, stimulated them with two immune-bo…
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 08:09 UTC
-
Promising prostate cancer combo trial halted before results
Disease control TerminatedThis phase 2 trial tested two drugs—cabozantinib and abiraterone—together in 54 men with castration-resistant prostate cancer that had spread to bones. The goal was to see if the combination could delay cancer growth. However, the study was stopped early by the sponsor for busine…
Phase: PHASE2 • Sponsor: Exelixis • Aim: Disease control
Last updated Jun 27, 2026 08:09 UTC
-
Promising combo for Hard-to-Treat cancers hits early snag
Disease control TerminatedThis study tested a combination of two drugs, copanlisib and fulvestrant, in people with advanced hormone receptor-positive (ER+ and/or PR+) cancers of the ovary, endometrium, or breast that also have certain genetic changes (PI3K/PTEN). Only 7 people took part before the study w…
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 08:09 UTC
-
Cancer drug cocktail shows promise for uterine tumors, but trial halted early
Disease control TerminatedThis study tested a new drug combination for people with advanced endometrial cancer or uterine sarcoma who had not yet received treatment. The combination included an immunotherapy drug (TQB2450) plus chemotherapy, with or without a targeted therapy (anlotinib). The goal was to …
Phase: PHASE2 • Sponsor: Chia Tai Tianqing Pharmaceutical Group Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 08:09 UTC
-
Promising cancer drug trial halted early: what happened?
Disease control TerminatedThis study tested a drug called Promitil in 19 people with ovarian or pancreatic cancer that had specific gene mutations (BRCA or HRD) and had stopped responding to first treatment. The goal was to see if Promitil could control tumor growth safely. The trial was terminated early,…
Phase: PHASE2 • Sponsor: Lipomedix Pharmaceuticals Inc. • Aim: Disease control
Last updated Jun 27, 2026 08:09 UTC
-
Gentler surgery for cervical cancer shows promise, study halted early
Disease control TerminatedThis study looked at whether a less invasive surgery (conservative surgery) could safely treat women with early-stage, low-risk cervical cancer. The goal was to see if this approach causes fewer side effects and helps recovery. The study included 137 women with stage IA2 or IB1 c…
Phase: NA • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 08:09 UTC
-
Radioactive 'Smart Bomb' for tumours tested in early trial
Disease control TerminatedThis early-phase trial tested a radioactive drug designed to seek out and destroy cancer cells in people with advanced solid tumours that had stopped responding to other treatments. The drug targets a protein called IGF-1R found on many cancer cells. The study aimed to find a saf…
Phase: PHASE1 • Sponsor: Fusion Pharmaceuticals Inc. • Aim: Disease control
Last updated Jun 27, 2026 08:08 UTC
-
New hope for kids with rare hormone disorder: drug may cut steroid doses
Disease control TerminatedThis study tested an experimental drug called tildacerfont in 67 children aged 2 to 17 with congenital adrenal hyperplasia (CAH), a genetic condition that disrupts hormone production. The goal was to see if adding this once-daily pill to standard steroid treatment could improve d…
Phase: PHASE2 • Sponsor: Spruce Biosciences • Aim: Disease control
Last updated Jun 27, 2026 08:06 UTC
-
Experimental cancer drug KZR-261 tested in early trial
Disease control TerminatedThis early-phase study tested a new drug called KZR-261 in 61 people with advanced solid tumors that had stopped responding to standard treatments. The main goals were to check safety, find the right dose, and see if the drug could shrink tumors. The trial was terminated, but the…
Phase: PHASE1 • Sponsor: Kezar Life Sciences, Inc. • Aim: Disease control
Last updated Jun 27, 2026 08:05 UTC
-
Endometrial cancer drug trial halted early: letrozole shows no clear benefit
Disease control TerminatedThis study aimed to see if taking letrozole (a hormone therapy) after standard treatment could help prevent endometrial cancer from coming back in patients with a non-specific molecular profile. The trial was stopped early after enrolling only 12 participants, so no firm conclusi…
Phase: PHASE2, PHASE3 • Sponsor: Fudan University • Aim: Disease control
Last updated Jun 27, 2026 08:04 UTC
-
Prostate cancer vaccine trial halted early – did it work?
Disease control TerminatedThis study tested a vaccine called PROSTVAC-V/F in 33 men who had their prostate removed due to cancer and were at high risk of the cancer returning. The goal was to see if the vaccine could keep cancer from coming back. The study was stopped early, so results are limited, but it…
Phase: PHASE2 • Sponsor: Medical University of South Carolina • Aim: Disease control
Last updated Jun 27, 2026 08:03 UTC
-
Measles virus takes on ovarian cancer in early trial
Disease control TerminatedThis phase 2 trial tested a genetically modified measles virus (MV-NIS) against standard chemotherapy in 17 women with ovarian, fallopian, or peritoneal cancer that no longer responded to platinum drugs. The virus was designed to infect and kill cancer cells while leaving healthy…
Phase: PHASE2 • Sponsor: Mayo Clinic • Aim: Disease control
Last updated Jun 27, 2026 08:03 UTC
-
Pelvic prolapse surgery showdown: which method causes less leakage?
Disease control TerminatedThis study compared two surgical procedures for treating pelvic organ prolapse in women aged 50-80. One method uses a vaginal approach (sacrospinofixation) and the other uses keyhole surgery through the abdomen (laparoscopic promontofixation). The goal was to see which causes les…
Phase: NA • Sponsor: Centre Hospitalier Universitaire de Nīmes • Aim: Disease control
Last updated Jun 27, 2026 08:00 UTC
-
Cancer drug combo trial halted early – what we know
Disease control TerminatedThis trial tested a combination of two drugs, rucaparib and atezolizumab, in 130 adults with advanced solid tumors that have specific DNA repair problems or are sensitive to platinum chemotherapy. The goal was to see if the combination could shrink tumors. However, the study was …
Phase: PHASE2 • Sponsor: Gustave Roussy, Cancer Campus, Grand Paris • Aim: Disease control
Last updated Jun 27, 2026 08:00 UTC
-
Ovarian cancer drug trial halted early: what happened?
Disease control TerminatedThis study aimed to see if the drug niraparib works better than standard chemotherapy before surgery for people with a specific type of advanced ovarian cancer (stage III or IV with HRd). The trial was planned for 36 participants but was stopped early. Researchers wanted to measu…
Phase: PHASE2 • Sponsor: Tesaro, Inc. • Aim: Disease control
Last updated Jun 27, 2026 08:00 UTC
-
New cancer drug BLU-222 tested in early trial – but study stopped early
Disease control TerminatedThis early-phase trial tested a new drug called BLU-222, alone or with other medicines, in about 50 people with advanced solid tumors (including certain breast, ovarian, and stomach cancers). The goal was to find a safe dose and see if it shrinks tumors. However, the study was te…
Phase: PHASE1 • Sponsor: Blueprint Medicines Corporation • Aim: Disease control
Last updated Jun 27, 2026 08:00 UTC
-
Experimental drug pacritinib tested for returning prostate cancer – but trial stopped early
Disease control TerminatedThis phase 2 trial tested the drug pacritinib in 6 men whose prostate cancer had come back after surgery or radiation, shown by rising PSA levels. The goal was to see if the drug could delay further cancer growth. However, the study was terminated early, so we have limited inform…
Phase: PHASE2 • Sponsor: Medical College of Wisconsin • Aim: Disease control
Last updated Jun 27, 2026 07:58 UTC
-
New 12-Week hormone therapy studied for rare tumors
Disease control TerminatedThis early-phase study tested a new formulation of octreotide (Debio 4126) that lasts 12 weeks, aiming to control hormone levels in people with acromegaly or certain neuroendocrine tumors. Only 19 participants were enrolled before the trial was terminated. The main goal was to me…
Phase: PHASE1 • Sponsor: Debiopharm International SA • Aim: Disease control
Last updated Jun 27, 2026 07:58 UTC
-
Promising cancer combo trial halted early
Disease control TerminatedThis study tested a new drug called SOT101 (nanrilkefusp alfa) combined with pembrolizumab in 166 people with advanced solid tumors like lung, colon, and ovarian cancer. The goal was to see if the combo could shrink tumors. The trial was stopped early, so results are limited.
Phase: PHASE2 • Sponsor: SOTIO Biotech AG • Aim: Disease control
Last updated Jun 27, 2026 07:58 UTC
-
New cancer drug trial halted early
Disease control TerminatedThis early-stage study tested a new drug called BDC-3042, alone or with another drug (cemiplimab), in 17 people with advanced cancers like breast, kidney, ovarian, head and neck, colorectal, lung, or melanoma. The main goal was to check safety and find the right dose. The study w…
Phase: PHASE1 • Sponsor: Bolt Biotherapeutics, Inc. • Aim: Disease control
Last updated Jun 27, 2026 07:57 UTC
-
Experimental HIV therapy aims to free patients from daily pills
Disease control TerminatedThis early-stage trial tests two experimental vaccines, HB-502 and HB-501, designed to teach the immune system to recognize and attack HIV. The study includes 30 people with HIV who are already on suppressive antiretroviral therapy. Participants receive injections every 8 weeks f…
Phase: PHASE1 • Sponsor: Hookipa Biotech GmbH • Aim: Disease control
Last updated Jun 27, 2026 07:57 UTC
-
New pill shows promise against tough breast and ovarian cancers
Disease control TerminatedThis study tested an experimental drug (PF-06873600) taken by mouth, alone or with hormone therapy, in people with advanced breast or ovarian cancers. The goal was to check safety and see if the drug could shrink tumors. The trial was stopped early, but results help guide future …
Phase: PHASE1, PHASE2 • Sponsor: Pfizer • Aim: Disease control
Last updated Jun 27, 2026 07:57 UTC
-
Experimental cancer drug study halted early
Disease control TerminatedThis study tested an experimental drug called SQ3370 in 53 people with advanced solid tumors that had spread or could not be removed by surgery. The goal was to check the drug's safety and find the best dose, as well as see if it could shrink tumors. The study was terminated earl…
Phase: PHASE1, PHASE2 • Sponsor: Shasqi, Inc. • Aim: Disease control
Last updated Jun 27, 2026 07:57 UTC
-
Can a Two-Drug punch restore sensitivity in Hard-to-Treat prostate cancer?
Disease control TerminatedThis early-phase trial tested whether adding decitabine/cedazuridine to enzalutamide could help men with metastatic castration-resistant prostate cancer whose cancer had stopped responding to enzalutamide alone. Only 8 men were enrolled before the study was terminated. The goal w…
Phase: PHASE1 • Sponsor: Roswell Park Cancer Institute • Aim: Disease control
Last updated Jun 27, 2026 07:57 UTC
-
HIV drug extension study halted early: what happened?
Disease control TerminatedThis study looked at whether weekly injections of PRO 140, taken with standard HIV medications, could keep the virus under control over the long term. It enrolled 43 people who had already completed an earlier PRO 140 study and had undetectable virus levels. The study was termina…
Phase: PHASE2, PHASE3 • Sponsor: CytoDyn, Inc. • Aim: Disease control
Last updated Jun 27, 2026 07:57 UTC
-
Experimental prostate cancer vaccine trial halted early
Disease control TerminatedThis early-phase trial tested an experimental immunotherapy called VTP-850 in 22 men whose prostate cancer had returned (shown by rising PSA levels) after initial treatment like surgery or radiation. The therapy used two modified viruses to train the immune system to attack prost…
Phase: PHASE1, PHASE2 • Sponsor: Barinthus Biotherapeutics • Aim: Disease control
Last updated Jun 27, 2026 07:56 UTC
-
Cancer drug trial halted midway: what happened?
Disease control TerminatedThis study tested an experimental drug called VLS-101 in 102 people with advanced solid tumors, including breast, lung, ovarian, stomach, and pancreatic cancers that had stopped responding to standard treatments. The goal was to see if the drug could shrink tumors. However, the t…
Phase: PHASE2 • Sponsor: VelosBio Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) • Aim: Disease control
Last updated Jun 27, 2026 07:56 UTC
-
Cancer-Fighting super cells tested in solid tumors – study halted early
Disease control TerminatedThis study tested a personalized treatment where a patient's own immune cells were modified in a lab to recognize and attack unique markers on their cancer cells. It involved 8 people with advanced solid tumors like lung, pancreatic, or ovarian cancer that had not responded to st…
Phase: PHASE1, PHASE2 • Sponsor: Alaunos Therapeutics • Aim: Disease control
Last updated Jun 27, 2026 07:56 UTC
-
Experimental cancer drug ART0380 trial halted early
Disease control TerminatedThis study tested an experimental drug called ART0380 in 36 people with advanced or metastatic solid tumors, including endometrial cancer. The drug was taken by mouth and aimed to shrink tumors by blocking a protein involved in cancer cell growth. The trial was terminated early, …
Phase: PHASE2 • Sponsor: Artios Pharma Ltd • Aim: Disease control
Last updated Jun 27, 2026 07:56 UTC
-
New cancer drug trial halted early – what we know
Disease control TerminatedThis early-stage trial tested an experimental drug called NUV-868, alone or with other cancer drugs, in 82 adults with advanced solid tumors (including ovarian, pancreatic, prostate, and breast cancers). The goal was to find safe doses and check for early signs of effectiveness. …
Phase: PHASE1 • Sponsor: Nuvation Bio Inc. • Aim: Disease control
Last updated Jun 27, 2026 07:56 UTC
-
Prostate cancer drug trialed to reduce steroids in kids with rare hormone disorder
Disease control TerminatedThis early-phase study tested a drug called abiraterone acetate (normally used for prostate cancer) in 4 children with congenital adrenal hyperplasia (CAH). The goal was to see if it could lower high male hormone levels and reduce the need for strong steroid medications that can …
Phase: PHASE1 • Sponsor: University of Texas Southwestern Medical Center • Aim: Disease control
Last updated Jun 27, 2026 07:56 UTC
-
Experimental cancer drug LY3405105 fails to advance in early trial
Disease control TerminatedThis early-phase study tested the safety of an oral drug called LY3405105 in 54 people with advanced solid tumors. The trial was divided into two parts to find the right dose and to see if the drug could shrink tumors. However, the study was terminated early, meaning the drug did…
Phase: PHASE1 • Sponsor: Eli Lilly and Company • Aim: Disease control
Last updated Jun 27, 2026 07:56 UTC
-
HIV patients test weekly shots to replace daily pills
Disease control TerminatedThis study tested whether HIV patients who already had the virus under control could switch to weekly injections of leronlimab (PRO 140) instead of their usual daily pills. The goal was to see if the drug alone could keep the virus suppressed safely over a longer period. The tria…
Phase: PHASE2, PHASE3 • Sponsor: CytoDyn, Inc. • Aim: Disease control
Last updated Jun 27, 2026 07:56 UTC
-
Targeted drug shows promise for rare genetic cancers
Disease control TerminatedThis study tested a drug called niraparib in 22 adults with advanced solid tumors (like breast, lung, or pancreatic cancer) that have a specific genetic change called a PALB2 mutation. The goal was to see if the drug could shrink tumors or slow cancer growth. The study was stoppe…
Phase: PHASE2 • Sponsor: Tempus AI • Aim: Disease control
Last updated Jun 27, 2026 07:55 UTC
-
Can a drug combo let HIV patients ditch daily meds?
Disease control TerminatedThis study tested two experimental drugs, budigalimab and ABBV-382, in people with HIV who were stable on standard therapy. Participants stopped their usual HIV medications to see if the new drugs could keep the virus under control. The trial was terminated early, so it's unclear…
Phase: PHASE2 • Sponsor: AbbVie • Aim: Disease control
Last updated Jun 27, 2026 07:55 UTC
-
Experimental cancer drug INCB062079 tested in early trial
Disease control TerminatedThis early-phase trial tested a new drug called INCB062079 in 25 people with advanced liver cancer and other solid tumors. The main goal was to check safety and find the best dose. The study was terminated early, so results are limited.
Phase: PHASE1 • Sponsor: Incyte Corporation • Aim: Disease control
Last updated Jun 27, 2026 07:55 UTC
-
New HIV drug candidate GS-1219 tested in tiny early trial
Disease control TerminatedThis was a small, early-phase study testing an experimental HIV drug called GS-1219 in just 4 people living with HIV-1. The goal was to check the drug's safety and how well it fights the virus. The study was terminated early, so results are very limited.
Phase: PHASE1 • Sponsor: Gilead Sciences • Aim: Disease control
Last updated Jun 27, 2026 07:55 UTC
-
Experimental cancer drug trial halted early
Disease control TerminatedThis early-stage study tested a new drug called HFB301001 in 31 adults with advanced solid tumors (like sarcoma, kidney cancer, or melanoma) that had not responded to prior treatments. The main goal was to check the drug's safety and find the best dose. The study was terminated, …
Phase: PHASE1 • Sponsor: HiFiBiO Therapeutics • Aim: Disease control
Last updated Jun 27, 2026 07:55 UTC
-
New program aims to boost HIV medication adherence for medicaid patients
Disease control TerminatedThis study tested a program to help Virginia Medicaid enrollees with HIV fill their antiretroviral prescriptions on time. The program offered support from providers, pharmacies, and community groups, with extra help for those who were very late refilling. Only 4 people enrolled b…
Phase: NA • Sponsor: Virginia Commonwealth University • Aim: Disease control
Last updated Jun 27, 2026 07:55 UTC
-
Experimental cancer drug ZW171 tested in 32 patients, but study stopped early
Disease control TerminatedThis early-phase study tested a new drug called ZW171 in 32 people with advanced ovarian, lung, or other cancers that have a protein called mesothelin. The main goals were to check the drug's safety and find the right dose. The study was terminated early, so results are limited.
Phase: PHASE1 • Sponsor: Zymeworks BC Inc. • Aim: Disease control
Last updated Jun 27, 2026 07:55 UTC
-
New cancer drug trial halted early – what we know
Disease control TerminatedThis study tested an experimental drug called INCB057643 in 137 people with advanced cancers that had stopped responding to standard treatments. The goal was to find a safe dose and check for side effects, both when given alone and with other cancer drugs. The trial was terminate…
Phase: PHASE1, PHASE2 • Sponsor: Incyte Corporation • Aim: Disease control
Last updated Jun 27, 2026 07:55 UTC
-
New HIV drug trial halted early – what happened?
Disease control TerminatedThis study tested an experimental HIV drug called VH3739937 in 21 adults with HIV who had never taken HIV medication before. The goal was to see how well the drug lowered the virus level in the blood over a short time. The trial was stopped early, and results are limited.
Phase: PHASE2 • Sponsor: ViiV Healthcare • Aim: Disease control
Last updated Jun 27, 2026 07:55 UTC
-
Experimental cancer drug trial ends early
Disease control TerminatedThis early-stage study tested an experimental drug called INCB099318 in people with advanced solid tumors that had stopped responding to standard treatments. The main goal was to check the drug's safety and how the body processes it. The study was terminated early, so results are…
Phase: PHASE1 • Sponsor: Incyte Corporation • Aim: Disease control
Last updated Jun 27, 2026 07:54 UTC
-
New drug tested for tough cancers
Disease control TerminatedThis early-stage study tested a new drug called ACTM-838 in 10 people with advanced solid tumors that no longer responded to standard treatments. The main goals were to check safety and find the right dose. The study was stopped early, so results are limited.
Phase: PHASE1 • Sponsor: Actym Therapeutics, Inc. • Aim: Disease control
Last updated Jun 27, 2026 07:54 UTC
-
New drug targets Hard-to-Treat prostate cancer in early trial
Disease control TerminatedThis early-phase study tested a new drug called acapatamab in 212 men with advanced prostate cancer that had stopped responding to standard hormone therapy and chemotherapy. The drug works by helping the body's immune cells attack cancer cells. The main goals were to check safety…
Phase: PHASE1 • Sponsor: Amgen • Aim: Disease control
Last updated Jun 27, 2026 07:54 UTC
-
Early cancer drug trial halted after just 3 patients
Disease control TerminatedThis early-stage study tested a new drug called AMG 794 in adults with advanced lung, ovarian, or other solid tumors that have a specific protein (claudin 6). The main goals were to check safety and find the right dose. However, the study was stopped early after only 3 people enr…
Phase: PHASE1 • Sponsor: Amgen • Aim: Disease control
Last updated Jun 27, 2026 07:54 UTC
-
Amgen's master trial for Hard-to-Treat prostate cancer hits early hurdles
Disease control TerminatedThis master trial tested several drug combinations, including a new targeted therapy called acapatamab, in 65 men with metastatic castration-resistant prostate cancer (mCRPC). The goal was to check safety and early signs of effectiveness. The study was terminated early, so result…
Phase: PHASE1, PHASE2 • Sponsor: Amgen • Aim: Disease control
Last updated Jun 27, 2026 07:53 UTC
-
HIV Antibody-Only therapy falls short in Long-Term trial
Disease control TerminatedThis study tested whether a single antibody called PRO 140 could keep HIV under control in 20 adults who had been stable on standard combination therapy. Participants stopped their usual HIV pills and received only PRO 140 infusions. The trial was stopped early, and the main goal…
Phase: PHASE2 • Sponsor: CytoDyn, Inc. • Aim: Disease control
Last updated Jun 27, 2026 07:53 UTC
-
Can a lower dose of prostate cancer drug work just as well?
Disease control TerminatedThis study looked at whether men with prostate cancer could take a lower dose of the drug abiraterone (combined with prednisone) and still control their cancer. About 50 men who had never taken abiraterone before were enrolled. The goal was to find the smallest dose that still lo…
Phase: PHASE1 • Sponsor: University of Chicago • Aim: Disease control
Last updated Jun 27, 2026 07:53 UTC
-
New drug aims to cut steroid use in rare hormone disorder
Disease control TerminatedThis study tested a daily tablet called Tildacerfont in 100 adults with classic congenital adrenal hyperplasia, a condition where the body can't make certain hormones properly. The goal was to see if the drug could safely reduce the high doses of steroids patients need to take. T…
Phase: PHASE2 • Sponsor: Spruce Biosciences • Aim: Disease control
Last updated Jun 27, 2026 07:53 UTC
-
Promising cancer combo study halted early – only 4 black women enrolled
Disease control TerminatedThis study aimed to see if a combination of two drugs, lenvatinib and pembrolizumab, could shrink tumors in Black women with a certain type of recurrent endometrial cancer. Only 4 participants were enrolled before the study was stopped early. The goal was to measure how many pati…
Phase: PHASE2 • Sponsor: Virginia Commonwealth University • Aim: Disease control
Last updated Jun 27, 2026 07:52 UTC
-
Exercise program targets metabolic risks in cancer survivors
Disease control TerminatedThis study looked at whether a specific type of exercise, combining aerobic and resistance training in short bursts, could improve metabolic health in overweight or obese breast and prostate cancer survivors who had finished treatment. The goal was to reduce insulin resistance an…
Phase: NA • Sponsor: University of Southern California • Aim: Disease control
Last updated Jun 27, 2026 07:52 UTC
-
New pill targets Hard-to-Treat cancers in early human test
Disease control TerminatedThis early-phase trial tested an experimental oral drug called NKT3447 in 23 adults with advanced or metastatic solid tumors that had stopped responding to standard treatments. The goal was to check safety, find the right dose, and see if the drug could shrink tumors. The study w…
Phase: PHASE1 • Sponsor: NiKang Therapeutics, Inc. • Aim: Disease control
Last updated Jun 27, 2026 07:52 UTC
-
Cancer drug study halted early: what we know
Disease control TerminatedThis study tested a new drug called LB101 in 25 adults with advanced solid tumors that had stopped responding to standard treatments. The goal was to check safety and see if the drug shrank tumors. The study was terminated early, so results are limited.
Phase: PHASE1, PHASE2 • Sponsor: Centessa Pharmaceuticals (UK) Limited • Aim: Disease control
Last updated Jun 27, 2026 07:51 UTC
-
Experimental ovarian cancer drug combo studied in early trial
Disease control TerminatedThis early-phase trial tested a new drug called STRO-002 combined with Avastin (bevacizumab) in 58 people with advanced ovarian, fallopian tube, or primary peritoneal cancer. The main goals were to check safety and find the right dose. The study was terminated early, so while it …
Phase: PHASE1 • Sponsor: Sutro Biopharma, Inc. • Aim: Disease control
Last updated Jun 27, 2026 07:51 UTC
-
New hope for tough ovarian cancer? trial tests smart drug vs chemo
Disease control TerminatedThis study tested a new drug called luveltamab tazevibulin (STRO-002) against standard chemotherapy in 600 women with ovarian cancer that had stopped responding to platinum treatment. The drug targets a protein (FOLR1) found on many ovarian cancer cells. The trial was terminated …
Phase: PHASE2, PHASE3 • Sponsor: Sutro Biopharma, Inc. • Aim: Disease control
Last updated Jun 27, 2026 07:51 UTC
-
Pfizer's new cancer combo shows early promise but trial halted
Disease control TerminatedThis early-stage trial tested a new drug, PF-07820435, alone or with another immunotherapy (sasanlimab) in 9 people with advanced solid tumors like lung, skin, or kidney cancer. The main goals were to check safety and find the right dose. The study was terminated early, so result…
Phase: PHASE1 • Sponsor: Pfizer • Aim: Disease control
Last updated Jun 26, 2026 18:06 UTC
-
Personalized cell therapy shows promise for tough cervical cancers
Disease control TerminatedThis phase 2 study tested a personalized treatment called LN-145 for women with recurrent or advanced cervical cancer. The therapy uses a patient's own tumor-fighting immune cells, grown in a lab and infused back. The trial aimed to see if it could shrink tumors, but it was termi…
Phase: PHASE2 • Sponsor: Iovance Biotherapeutics, Inc. • Aim: Disease control
Last updated Jun 26, 2026 18:04 UTC
-
Experimental cancer combo trial halted early – what it means for patients
Disease control TerminatedThis early-stage trial tested a new drug called BDC-1001, alone or with the immunotherapy nivolumab, in 175 people with advanced HER2-positive cancers (like breast, colorectal, and stomach cancers) that had stopped responding to other treatments. The study aimed to check safety a…
Phase: PHASE1, PHASE2 • Sponsor: Bolt Biotherapeutics, Inc. • Aim: Disease control
Last updated Jun 26, 2026 17:13 UTC
-
Experimental prostate cancer combo trial halted early
Disease control TerminatedThis early-phase trial tested a new immunotherapy drug called vudalimab (XmAb20717) alongside standard treatments for men with metastatic castration-sensitive prostate cancer. The study aimed to check safety and early signs of effectiveness. However, the trial was terminated earl…
Phase: PHASE1 • Sponsor: Emory University • Aim: Disease control
Last updated Jun 26, 2026 17:03 UTC
-
New pill for advanced prostate cancer shows early promise, but trial halted
Disease control TerminatedThis study tested an oral drug called LAE001 in 33 men with metastatic prostate cancer that had stopped responding to standard hormone therapy. The goal was to check safety and find the right dose, and to see if the drug could lower PSA levels. The trial was terminated early, so …
Phase: PHASE1, PHASE2 • Sponsor: Laekna Limited • Aim: Disease control
Last updated Jun 26, 2026 15:36 UTC
-
Fatty liver drug trial in HIV patients stalls after enrolling just 4 people
Disease control TerminatedThis study tested a drug called saroglitazar magnesium for nonalcoholic fatty liver disease (NAFLD) in people with HIV. The trial aimed to see if the drug could reduce liver fat over 24 weeks. However, the study was terminated early and only enrolled 4 participants, so no meaning…
Phase: PHASE2 • Sponsor: Zydus Therapeutics Inc. • Aim: Disease control
Last updated Jun 26, 2026 12:33 UTC
-
New blood test aims to catch live prostate cancer cells
Diagnosis TerminatedThis study tests a new blood test called EPIDROP that looks for live circulating tumor cells in men with metastatic prostate cancer. The test uses a special technique to isolate single cells and measure their activity. Researchers want to see if EPIDROP is as good as or better th…
Phase: NA • Sponsor: University Hospital, Montpellier • Aim: Diagnosis
Last updated Jun 27, 2026 14:01 UTC
-
Triple imaging technique aims to sharpen prostate cancer detection
Diagnosis TerminatedThis study tested a new way to guide prostate biopsies by combining three imaging methods: a PET scan using a special tracer (fluorocholine), multiparametric MRI, and 3D ultrasound. The goal was to see if this triple approach could more accurately target suspicious areas in the p…
Phase: NA • Sponsor: Lille Catholic University • Aim: Diagnosis
Last updated Jun 27, 2026 13:07 UTC
-
New PSMA scan aims to spot hidden prostate cancer spread
Diagnosis TerminatedThis study tested whether a special type of PET/CT scan, called PSMA PET/CT, can better detect if prostate cancer has spread to nearby lymph nodes before surgery. The scan uses a radioactive tracer that sticks to prostate cancer cells, making them visible. The goal was to help do…
Phase: NA • Sponsor: University Hospital, Brest • Aim: Diagnosis
Last updated Jun 27, 2026 13:06 UTC
-
Fewer biopsy cores may be safer and just as accurate for prostate cancer detection
Diagnosis TerminatedThis study looked at whether taking fewer systematic biopsy cores (6 instead of 20) during an MRI-targeted prostate biopsy could still detect dangerous prostate cancers while reducing risks like infection and overdiagnosis. The trial involved 126 men with suspicious MRI results. …
Phase: NA • Sponsor: IRCCS San Raffaele • Aim: Diagnosis
Last updated Jun 27, 2026 13:06 UTC
-
Pee test could replace pap smear for some women
Diagnosis TerminatedThis study tested whether offering a home urine test for human papillomavirus (HPV) could encourage more women to get screened for cervical cancer. The trial targeted women aged 30–65 in Brittany, France, who had not responded to an initial invitation for a Pap smear. Participant…
Phase: NA • Sponsor: University Hospital, Brest • Aim: Diagnosis
Last updated Jun 27, 2026 13:05 UTC
-
New scan could sharpen ovarian cancer detection
Diagnosis TerminatedThis study tested whether a new radioactive tracer called FAPI-46, used with a PET/CT scan, can more accurately detect the spread of ovarian cancer compared to standard scans. Researchers planned to enroll 50 women with newly diagnosed ovarian cancer, but the study was terminated…
Phase: PHASE2 • Sponsor: Aalborg University Hospital • Aim: Diagnosis
Last updated Jun 27, 2026 12:37 UTC
-
New oral test could replace painful insulin injections for hormone diagnosis
Diagnosis TerminatedThis study tested a new oral drink (GS3-007a) to diagnose adult growth hormone deficiency (AGHD). It compared the drink to the standard insulin tolerance test in 120 adults suspected of having AGHD and healthy volunteers. The goal was to see if the oral test works as well as the …
Phase: PHASE2 • Sponsor: Changchun GeneScience Pharmaceutical Co., Ltd. • Aim: Diagnosis
Last updated Jun 27, 2026 12:37 UTC
-
New PET scan agent aims to map hidden prostate cancer spread
Diagnosis TerminatedThis study tested a new imaging agent called 68Ga-PSMA-11 to see if it could give clearer pictures of where prostate cancer has spread in men with advanced, treatment-resistant disease. The goal was to help doctors better understand the location of tumors. The study was terminate…
Phase: PHASE2 • Sponsor: Thomas Hope • Aim: Diagnosis
Last updated Jun 27, 2026 12:33 UTC
-
New ovarian imaging could cut unneeded surgeries by 23%
Diagnosis TerminatedThis study tested whether adding photoacoustic imaging to standard ultrasound can better tell if an ovary is cancerous or benign. Researchers aimed to reduce the number of women who have surgery to remove an ovary that turns out to be non-cancerous. The study enrolled 185 women s…
Phase: NA • Sponsor: Washington University School of Medicine • Aim: Diagnosis
Last updated Jun 27, 2026 12:30 UTC
-
New MRI dye could spot hidden prostate cancer cells
Diagnosis TerminatedThis phase 3 trial tested whether an iron-based contrast agent called Ferumoxtran-10 (Ferrotran®) could improve MRI scans to find prostate cancer that has spread to lymph nodes. The study involved 172 men with newly diagnosed prostate cancer at intermediate to high risk of spread…
Phase: PHASE3 • Sponsor: Saving Patients' Lives Medical B.V. • Aim: Diagnosis
Last updated Jun 27, 2026 12:24 UTC
-
New embryo test could boost IVF success without poking the embryo
Diagnosis TerminatedThis study tested a new, non-invasive way to check embryos for chromosome problems before IVF. Instead of taking a cell from the embryo, doctors analyzed the fluid the embryo grew in. The goal was to see if this method could help choose the embryo most likely to lead to a healthy…
Phase: NA • Sponsor: Igenomix • Aim: Diagnosis
Last updated Jun 27, 2026 07:52 UTC
-
Tiny trial on preventive bladder sling halted early — no clear answers
Prevention TerminatedThis study looked at women with pelvic organ prolapse who also had hidden (occult) stress urinary incontinence — leakage that doesn't show up on standard tests. The goal was to see if placing a TOT sling during prolapse surgery could prevent incontinence from appearing later. The…
Phase: NA • Sponsor: Assistance Publique - Hôpitaux de Paris • Aim: Prevention
Last updated Jun 28, 2026 00:00 UTC
-
Skin-Saving paste for cancer radiation falls short in tiny trial
Prevention TerminatedThis study tested whether Alkagin paste could prevent skin damage in patients receiving radiation for anal, rectal, or gynecological cancers. Only 2 people enrolled before the trial was stopped early. Because of this, we cannot draw any reliable conclusions about the paste's effe…
Phase: PHASE2 • Sponsor: Sir Mortimer B. Davis - Jewish General Hospital • Aim: Prevention
Last updated Jun 27, 2026 12:32 UTC
-
Monthly HIV prevention pill trial halted Mid-Study
Prevention TerminatedThis study tested a once-monthly pill called islatravir to prevent HIV infection in cisgender men and transgender women who have sex with men and are at high risk. About 494 participants were enrolled, but the trial was terminated early. The main goal was to check safety and see …
Phase: PHASE3 • Sponsor: Merck Sharp & Dohme LLC • Aim: Prevention
Last updated Jun 27, 2026 12:29 UTC
-
Phone app aims to boost HIV testing in young black men and transwomen
Prevention TerminatedThis study tested a mobile-friendly tool that helps young Black men and transwomen who have sex with men or transwomen pick the best HIV testing method for them, such as self-testing or clinic testing. The goal was to see if this personalized recommendation could increase how oft…
Phase: NA • Sponsor: New York Blood Center • Aim: Prevention
Last updated Jun 27, 2026 12:05 UTC
-
New approach aims to boost HIV prevention in LGBTQ+ individuals struggling with addiction
Prevention TerminatedThis study tested a program to help HIV-negative transgender women and men who have sex with men who also have a substance use disorder stick with PrEP, a daily pill or shot that prevents HIV. Participants received counseling and text support, with extra help for those who strugg…
Phase: NA • Sponsor: Friends Research Institute, Inc. • Aim: Prevention
Last updated Jun 27, 2026 09:04 UTC
-
Monthly HIV prevention pill tested in women – study halted early
Prevention TerminatedThis study tested a new monthly pill (islatravir) to see if it could prevent HIV infection better than a daily pill in 730 women at high risk. The trial was stopped early, so results are limited. The goal was to offer a more convenient prevention option.
Phase: PHASE3 • Sponsor: Merck Sharp & Dohme LLC • Aim: Prevention
Last updated Jun 27, 2026 09:01 UTC
-
Hope for rare hunger disorder: new drug enters final testing phase
Symptom relief TerminatedThis phase 3 trial tests whether ARD-101 can reduce the intense, constant hunger (hyperphagia) seen in Prader-Willi syndrome. About 90 participants will take either ARD-101 or a placebo daily for 12 weeks. Caregivers will track changes in hunger-related behaviors using a standard…
Phase: PHASE3 • Sponsor: Aardvark Therapeutics, Inc. • Aim: Symptom relief
Last updated Jul 02, 2026 00:00 UTC
-
Antibiotic after surgery fails to prove pain relief for endometriosis
Symptom relief TerminatedThis study tested whether taking a low dose of the antibiotic metronidazole for 14 days after endometriosis surgery could lower pain. It included 78 women aged 18-50 scheduled for surgery. The trial was terminated early, so the results are not conclusive.
Phase: PHASE4 • Sponsor: University of Louisville • Aim: Symptom relief
Last updated Jun 27, 2026 14:00 UTC
-
No-Pill pain control: Opioid-Free approach after prostate surgery
Symptom relief TerminatedThis study tested whether a combination of non-opioid medicines (ketamine, ketorolac, and acetaminophen) can control pain after robotic prostatectomy as well as standard opioid painkillers. Men aged 40-75 with prostate cancer were randomly assigned to receive either opioids or th…
Phase: PHASE2, PHASE3 • Sponsor: Wake Forest University Health Sciences • Aim: Symptom relief
Last updated Jun 27, 2026 14:00 UTC
-
Youth HIV study tests talking circles for better mental health
Symptom relief TerminatedThis study tested whether a group therapy program, led by trained youth leaders, could improve mental health and help young people with HIV stick to their medication. About 484 youth in low-resource settings took part. The program used trauma-informed counseling adapted to local …
Phase: NA • Sponsor: International Maternal Pediatric Adolescent AIDS Clinical Trials Group • Aim: Symptom relief
Last updated Jun 27, 2026 12:37 UTC
-
Mouthwash may fight Chemo's bitter side effect
Symptom relief TerminatedThis pilot study tested a mouthwash made with homoeriodictyol sodium to reduce bitter taste caused by chemotherapy in women with gynecologic cancers. The study aimed to see if the mouthwash could improve taste and food intake. Only 15 participants were enrolled, and the trial was…
Phase: NA • Sponsor: Christoph Grimm • Aim: Symptom relief
Last updated Jun 27, 2026 12:31 UTC
-
CBDV study for Prader-Willi syndrome halted early
Symptom relief TerminatedThis study tested whether a cannabis-derived compound called CBDV could safely reduce irritability in children and young adults with Prader-Willi syndrome. Only 6 people enrolled before the study was stopped early. The goal was to see if CBDV helped with mood and behavior problem…
Phase: PHASE2 • Sponsor: Eric Hollander • Aim: Symptom relief
Last updated Jun 27, 2026 12:30 UTC
-
Herbal brew for early puberty? trial ends early
Symptom relief TerminatedThis study tested a traditional Chinese herbal formula called Qingwei Huazhuo Decoction in 94 girls with mild early puberty (breast development starting too soon). The goal was to see if the herbs could slow breast growth and bone age. However, the trial was terminated early, so …
Phase: NA • Sponsor: Children's Hospital of Fudan University • Aim: Symptom relief
Last updated Jun 27, 2026 12:29 UTC
-
Can less pressure mean better fibroid surgery?
Symptom relief TerminatedThis study looked at whether using a lower fluid pressure (60 mmHg) during hysteroscopy, a procedure to remove fibroids, works as well as the standard pressure (80 mmHg). The goal was to see if it improves surgery time, fluid use, and surgeon's view. The study was stopped early a…
Phase: NA • Sponsor: Northwestern University • Aim: Symptom relief
Last updated Jun 27, 2026 12:26 UTC
-
Fewer radiation sessions may mean fewer side effects for prostate cancer patients
Symptom relief TerminatedThis study looked at men with low or intermediate-risk prostate cancer to see if 2 MRI-guided radiation treatments cause fewer bowel and bladder side effects than 5 treatments. The goal was to find a shorter treatment plan that is just as safe and less bothersome. The study was s…
Phase: PHASE2 • Sponsor: Weill Medical College of Cornell University • Aim: Symptom relief
Last updated Jun 27, 2026 12:23 UTC
-
HIV-Positive Men's mental health study shuts down after just one participant
Symptom relief TerminatedThis study aimed to see if acceptance and commitment therapy (ACT), a type of talk therapy, could help HIV-positive men with mental health issues like stress and anxiety. Only one person enrolled before the study was stopped early. Because of this, no meaningful results were obta…
Phase: NA • Sponsor: University of Alabama at Birmingham • Aim: Symptom relief
Last updated Jun 27, 2026 12:09 UTC
-
Newer radiation technique may spare bladder and bowel in endometrial cancer patients
Symptom relief TerminatedThis trial compared two ways of giving pelvic radiotherapy after surgery for endometrial cancer: standard 3D planning versus a newer technique called IMRT. The goal was to see if IMRT could reduce side effects like bladder and bowel problems. The study enrolled 92 participants bu…
Phase: PHASE2 • Sponsor: Cancer Trials Ireland • Aim: Symptom relief
Last updated Jun 27, 2026 12:06 UTC
-
Can retelling and deep breathing ease trauma in terminal cancer?
Symptom relief TerminatedThis Phase 2 trial tested a neuroscience-based technique combining memory structuring and deep vagal breathing to reduce PTSD symptoms in people with advanced, incurable cancer and their partners. The study enrolled 19 patients who had just received a terminal diagnosis. The appr…
Phase: PHASE2 • Sponsor: Centre Oscar Lambret • Aim: Symptom relief
Last updated Jun 27, 2026 11:01 UTC
-
Estrogen cream studied for Post-Birth injury recovery
Symptom relief TerminatedThis study tested whether a topical estrogen cream could improve sexual function and reduce incontinence in women who had a severe tear during childbirth. Thirty-eight women used either the cream or a placebo for six months. The trial was terminated early, so the findings are lim…
Phase: PHASE4 • Sponsor: University of Alabama at Birmingham • Aim: Symptom relief
Last updated Jun 27, 2026 09:06 UTC
-
Tiny trial tests Talk-and-Movement therapy for pelvic pain
Symptom relief TerminatedThis study looked at whether a group therapy program combining psychotherapy and physiotherapy could help women with long-lasting pelvic or belly pain. Only 8 women took part, and the study was stopped early. Researchers measured changes in pain impact, daily activities, and emot…
Sponsor: Swiss Paraplegic Research, Nottwil • Aim: Symptom relief
Last updated Jun 27, 2026 09:02 UTC
-
Placental tissue implant tested to speed up erection recovery after prostate removal
Symptom relief TerminatedThis study tested whether placing a special placental tissue over nerves during prostate cancer surgery helps men regain erections and bladder control faster. Only 3 men participated before the study was stopped early. The approach aimed to protect nerves during surgery, but resu…
Phase: PHASE2 • Sponsor: Johns Hopkins University • Aim: Symptom relief
Last updated Jun 27, 2026 09:00 UTC
-
Can a Plant-Based pill soothe radiation side effects in prostate cancer?
Symptom relief TerminatedThis study looked at whether a supplement called Q-Urol (made from quercetin, bromelain, rye flower pollen, and papain) could reduce prostate inflammation caused by radiation therapy in men with localized prostate cancer. Ten men who had brachytherapy (with or without other radia…
Phase: PHASE2 • Sponsor: University of Utah • Aim: Symptom relief
Last updated Jun 27, 2026 09:00 UTC
-
Can the 'Female Viagra' boost Men's sex drive?
Symptom relief TerminatedThis small study tested whether flibanserin (Addyi), a drug approved for low sexual desire in women, could also help men with low libido. Eight men aged 18–69 with low desire but normal mood and erectile function took either the drug or a placebo for three months. The trial was t…
Phase: PHASE2 • Sponsor: Mohit Khera • Aim: Symptom relief
Last updated Jun 27, 2026 08:15 UTC
-
CBD shows promise for emotional health in HIV patients
Symptom relief TerminatedThis study tested whether synthetic cannabidiol (CBD) could help people living with HIV who have a condition called alexithymia, which makes it hard to recognize and describe emotions. Participants took either CBD or a placebo for 4 weeks. The goal was to see if CBD could improve…
Phase: PHASE2 • Sponsor: University of California, San Diego • Aim: Symptom relief
Last updated Jun 27, 2026 08:14 UTC
-
Can a simple pill replace abortion for late periods?
Symptom relief TerminatedThis study tested how acceptable it is to use misoprostol alone to start a late period. It included 17 adults whose period was up to 14 days late. The goal was to see if people were satisfied with this approach and if it worked to bring on their period.
Phase: PHASE4 • Sponsor: University of California, San Francisco • Aim: Symptom relief
Last updated Jun 27, 2026 08:13 UTC
-
Gentler cervical screening tool tested, but study cut short
Symptom relief TerminatedThis study compared two devices used to collect tissue from the cervix during screening for cervical cancer: the standard Kevorkian curette and a softer cytobrush. The goal was to see if the cytobrush causes less pain while still getting enough cells for diagnosis. Only 3 women w…
Phase: NA • Sponsor: University Hospital, Lille • Aim: Symptom relief
Last updated Jun 27, 2026 08:06 UTC
-
Massage therapy tested as fatigue fix for prostate cancer survivors
Symptom relief TerminatedThis phase II trial tested whether Swedish massage can reduce fatigue in men who have had radiation for prostate cancer. The study enrolled 28 men aged 45 and older who reported significant fatigue. Researchers measured fatigue levels and inflammatory markers before and after mas…
Phase: PHASE2 • Sponsor: University of Utah • Aim: Symptom relief
Last updated Jun 27, 2026 08:04 UTC
-
Radioactive treatment for bone pain in advanced prostate cancer tested, but study stopped early
Symptom relief TerminatedThis study tested a radioactive drug called Sn-117m-DTPA to see if it could reduce bone pain in men with prostate cancer that had spread to their bones and no longer responded to hormone therapy. Only one person enrolled before the study was stopped. The goal was to measure pain …
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Symptom relief
Last updated Jun 27, 2026 07:53 UTC
-
Prostate cancer treatment may change how men process common sleep aid
Knowledge-focused TerminatedThis pilot study looked at how the sleep drug zolpidem (Ambien) is processed in men with prostate cancer before and after they start hormone therapy that lowers testosterone. Researchers compared these results to healthy women, since women are known to have higher drug levels. Th…
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Knowledge-focused
Last updated Jun 28, 2026 00:00 UTC
-
Newborn death prediction tool for early membrane rupture falls short
Knowledge-focused TerminatedThis study tried to create a score that doctors could use before birth to predict whether a newborn would die after the mother's water broke very early (between 22 and 28 weeks of pregnancy). The researchers looked back at medical records of 34 women to find factors that might pr…
Sponsor: Centre Hospitalier Universitaire, Amiens • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:02 UTC
-
HIV patients may age faster: study probes skin, muscle, and bone health
Knowledge-focused TerminatedThis study compared signs of aging in 123 HIV-infected adults to the general population. Researchers measured bone density, muscle strength, skin changes, and thinking abilities. The goal was to understand if HIV speeds up aging in these areas. No new treatment was tested; it was…
Phase: NA • Sponsor: University Hospital, Bordeaux • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:02 UTC
-
Which scan spots prostate cancer best? new study puts two to the test
Knowledge-focused TerminatedThis study looked at 14 men with intermediate-risk prostate cancer who were scheduled for prostate removal surgery. Each man received two different types of PET scans to see which one better highlights cancer cells. The goal was to compare the scans' ability to detect and measure…
Phase: PHASE2 • Sponsor: University Hospital, Bordeaux • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:02 UTC
-
Hysterectomy study abandoned after just one patient
Knowledge-focused TerminatedThis study aimed to compare how often women could go home the same day after a hysterectomy using three different minimally invasive techniques: vNOTES (through the vagina), conventional laparoscopy, and robot-assisted laparoscopy. The trial was terminated early after enrolling o…
Phase: NA • Sponsor: Elsan • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:00 UTC
-
Brain and eye clues to emotion recognition in autism and psychosis
Knowledge-focused TerminatedThis study aimed to understand why people with autism or schizophrenia sometimes struggle to recognize emotions on faces. Researchers used brain wave recordings (EEG) and eye-tracking to see how participants processed facial expressions. The study included people with autism, sch…
Phase: NA • Sponsor: Hôpital le Vinatier • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:07 UTC
-
Does Dad's smoking harm fertility? new study investigates
Knowledge-focused TerminatedThis study looked at how a man's smoking habits might affect a couple's ability to have a baby. Researchers compared fertile and infertile couples, measuring smoking markers like carbon monoxide and cotinine in blood, semen, and hair. The goal was to understand if smoking damages…
Phase: NA • Sponsor: Centre Hospitalier Universitaire, Amiens • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:07 UTC
-
Tiny hairs in fallopian tubes may hold key to ectopic pregnancy
Knowledge-focused TerminatedThis study looks at the tiny hair-like structures (cilia) inside the fallopian tubes of women who have had surgery to remove a tube or uterus. Researchers want to see if differences in these cilia help explain why some women have ectopic pregnancies (when a fertilized egg grows o…
Phase: NA • Sponsor: Centre Hospitalier Intercommunal Creteil • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:06 UTC
-
Beetroot juice study for missed periods fizzles out
Knowledge-focused TerminatedThis study looked at whether beetroot juice, which is rich in nitrates, could improve muscle power and oxygen recovery in women who have stopped menstruating (secondary amenorrhea). The idea was that the lack of estrogen in these women lowers nitric oxide levels, and beetroot jui…
Phase: NA • Sponsor: Indiana University • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:05 UTC
-
Blood test may predict brain fog from prostate cancer treatment
Knowledge-focused TerminatedThis study aimed to see if a simple blood test could predict memory and thinking problems in men with prostate cancer receiving hormone therapy (ADT). Researchers planned to follow 32 men over time, comparing those on ADT to those not on it. The study was stopped early, so result…
Sponsor: University of California, San Francisco • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:30 UTC
-
Helping with food and housing may boost cancer screening Follow-Up
Knowledge-focused TerminatedThis study looked at whether providing support for unmet basic needs—like food, housing, or transportation—helps low-income women attend their colposcopy appointment after an abnormal cervical cancer screening. The trial planned to enroll 72 participants but was stopped early wit…
Phase: NA • Sponsor: Washington University School of Medicine • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:30 UTC
-
Scientists hunt for hidden cancer genes in young patients
Knowledge-focused TerminatedThis study aimed to find inherited gene changes in people diagnosed with cancer at a young age, including breast, ovarian, colorectal, and pediatric cancers. Researchers used a special test to look at 200 genes linked to cancer in 289 participants. The goal was to better understa…
Phase: NA • Sponsor: University Hospital, Rouen • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:29 UTC
-
Scientists investigate mpox in severely weakened immune systems
Knowledge-focused TerminatedThis study looked at how the mpox virus spreads and how the immune system responds in people with advanced HIV. Researchers tracked the virus in different body samples and measured immune markers to better understand severe illness. The goal is to use these findings to improve tr…
Sponsor: Centers for Disease Control and Prevention • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:29 UTC
-
Web tool aims to boost HIV testing among black women in the south
Knowledge-focused TerminatedThis study tested a web-based program to help Black women in Texas use HIV and STI home tests and connect to treatment or PrEP. The program included five sessions with goal-setting and action plans. Only 31 women enrolled before the study was stopped early, so the findings are li…
Phase: NA • Sponsor: Johns Hopkins Bloomberg School of Public Health • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:24 UTC
-
Ovarian cancer study reveals hidden struggles of patients and caregivers
Knowledge-focused TerminatedThis study looked at how platinum-resistant ovarian cancer affects the quality of life of patients and their caregivers in Canada. Researchers surveyed 24 patients and their caregivers using questionnaires to measure symptoms, daily challenges, and overall well-being. The goal wa…
Sponsor: PeriPharm • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:04 UTC
-
Ovarian cancer immune cells under microscope in terminated study
Knowledge-focused TerminatedThis study aimed to understand how immune cells in the blood, abdominal fluid, and tumor tissue change in women with advanced ovarian or fallopian tube cancer before and after chemotherapy. Researchers collected samples from 36 women to count different types of immune cells. The …
Phase: NA • Sponsor: Centre Oscar Lambret • Aim: Knowledge-focused
Last updated Jun 27, 2026 11:02 UTC
-
Chemo's toll on fertility: study in young breast cancer patients
Knowledge-focused TerminatedThis study aimed to understand how chemotherapy impacts the ability to have children in young women (ages 18-37) with breast cancer. Researchers measured ovarian reserve (egg supply) using hormone levels and follicle counts before, during, and up to 24 months after treatment. The…
Sponsor: Centre Oscar Lambret • Aim: Knowledge-focused
Last updated Jun 27, 2026 11:01 UTC
-
Early scan hopes to predict cervical cancer outcomes
Knowledge-focused TerminatedThis study looked at whether MRI and PET scans taken two weeks into radiotherapy can predict if cervical cancer will be controlled. Researchers measured tumor size and activity in 9 patients with stage I to IIIB cervical cancer. The goal was to find early signs of treatment failu…
Phase: NA • Sponsor: Centre Oscar Lambret • Aim: Knowledge-focused
Last updated Jun 27, 2026 11:01 UTC
-
Gene study probes infertility hormone clues
Knowledge-focused TerminatedThis study looked at how the body responds to certain hormones (kisspeptin and GnRH) in people who carry gene variants linked to infertility. Researchers measured natural hormone patterns and responses to stimulation in 16 participants. The goal was to better understand reproduct…
Phase: PHASE1 • Sponsor: Stephanie B. Seminara, MD • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:10 UTC
-
Can a video game teach surgeons to remove prostate cancer?
Knowledge-focused TerminatedThis study tested whether an online video simulator helps surgeons learn laparoscopic radical prostatectomy, a surgery for prostate cancer. It enrolled 29 surgeons who were new to the procedure, comparing those who used the simulator to those who did not. The trial was terminated…
Phase: NA • Sponsor: Assistance Publique - Hôpitaux de Paris • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:07 UTC
-
New test may expand olaparib benefits to more ovarian cancer patients
Knowledge-focused TerminatedThis study tested a new lab method (RAD51 assay) to see if it could identify ovarian cancer patients whose tumors are vulnerable to the drug olaparib, even if they don't have BRCA gene mutations. The goal was to find a larger group of patients who might benefit from this treatmen…
Phase: PHASE2 • Sponsor: Leiden University Medical Center • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:06 UTC
-
Fluid monitor study in prostate surgery stopped early
Knowledge-focused TerminatedThis study looked at whether a special monitor (CardioQ-ODM+) could help doctors give the right amount of fluids during robot-assisted prostate surgery. The surgery uses gas and a head-down position, which can affect how well standard fluid monitors work. The study planned to inc…
Phase: NA • Sponsor: Hallym University Kangnam Sacred Heart Hospital • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:00 UTC
-
Mesh study follows patients for years after prolapse surgery
Knowledge-focused TerminatedThis study followed 39 women who had surgery for pelvic organ prolapse using Restorelle mesh. The goal was to track safety and how well the mesh worked over 5 to 8 years after surgery. No new treatment was given—just routine check-ups to see if any further surgery was needed.
Sponsor: Coloplast A/S • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:00 UTC
-
Can cheap text messages boost HIV retesting? pilot study seeks answers
Knowledge-focused TerminatedThis pilot study tested several low-cost behavioral nudges, like videos and text messages, to encourage HIV retesting among 98 adults at higher risk of HIV in rural Kenya and Uganda. The goal was to see which approaches were acceptable and feasible, so the best ones could be used…
Phase: NA • Sponsor: University of California, San Francisco • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:14 UTC
-
Cancer drug interaction study halted after just one patient
Knowledge-focused TerminatedThis early-stage study aimed to see how the experimental drug ceralasertib affects the way the body processes three other drugs (Drug X, Y, and Z) in people with advanced solid tumours. Only one person was enrolled before the study was terminated, so no useful information was gat…
Phase: PHASE1 • Sponsor: AstraZeneca • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:12 UTC
-
Blood marker may predict prostate cancer drug response
Knowledge-focused TerminatedThis study aimed to see if a substance in the blood called uPAR can help predict how well men with advanced prostate cancer respond to the drug abiraterone. Only 3 men were enrolled before the study was stopped early. The goal was to find a simple blood test that could guide trea…
Sponsor: Kristoffer Rohrberg • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:11 UTC
-
Scientists tap cancer fluids for clues to better treatments
Knowledge-focused TerminatedThis study collected fluid from the abdomen or lungs, plus blood, from 22 adults with solid tumors. The goal was to learn more about cancer biology, not to provide a direct treatment. Researchers hope these samples will help them understand how cancer grows and lead to better the…
Sponsor: National Cancer Institute (NCI) • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:08 UTC
-
New fertility library aims to unlock secrets of unexplained infertility
Knowledge-focused TerminatedThis study aimed to create a library of biological samples and clinical data from 250 women with unexplained infertility or low ovarian reserve. Researchers collected blood, DNA, vaginal swabs, and fluid from egg retrieval to help future studies find markers that predict pregnanc…
Sponsor: University Hospital, Brest • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:05 UTC
-
Simple urine test could spot prostate cancer early
Knowledge-focused TerminatedThis study looked at whether DNA markers found in urine can help detect prostate cancer. Researchers collected urine and prostate fluid samples from 24 men with or suspected of having prostate cancer. The goal was to see how accurate these markers are and to understand patient op…
Sponsor: Mayo Clinic • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:04 UTC
-
New scan technique tested for prostate cancer radiation planning
Knowledge-focused TerminatedThis study tested whether combining two types of scans (PSMA-PET and MRI) can help doctors better target radiation for prostate cancer. The goal was to see if this approach is safe and possible. Only 8 people took part before the study was stopped early.
Phase: PHASE2 • Sponsor: UNC Lineberger Comprehensive Cancer Center • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:03 UTC
-
PCOS hormone study halted early – what it means for IVF
Knowledge-focused TerminatedThis study looked at whether high levels of male hormones (hyperandrogenism) lower the chance of IVF success in women with PCOS. Researchers planned to track 32 women aged 18–39, but the study was terminated early. The goal was to see if these hormones affect pregnancy rates afte…
Sponsor: Clinique Ovo • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:03 UTC
-
New imaging method aims to personalize pelvic floor disorder treatments
Knowledge-focused TerminatedThis study tested a new way to map the pelvic cavity in women using MRI and a special vaginal pressure probe. The goal was to better understand each woman's pelvic tissue characteristics so treatments like surgery or rehabilitation could be personalized. Only one participant was …
Phase: NA • Sponsor: University Hospital, Lille • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:03 UTC
-
New survey aims to better measure life quality in pituitary tumor patients
Knowledge-focused TerminatedThis study tested a new questionnaire called Prolac-10 to see if it can accurately measure quality of life in people with prolactinoma (a type of pituitary tumor) who are starting medical treatment. Only 8 people took part before the study was stopped early. The goal was to check…
Sponsor: Ohio State University • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:02 UTC
-
Hormone cream study aims to unlock pelvic floor secrets
Knowledge-focused TerminatedThis study looked at how hormones influence vaginal tissue in women with pelvic organ prolapse (POP), a condition where pelvic organs slip out of place. Researchers compared postmenopausal women using estrogen cream or placebo to reproductive-age women, examining tissue samples f…
Phase: PHASE4 • Sponsor: The University of Texas Medical Branch, Galveston • Aim: Knowledge-focused
Last updated Jun 27, 2026 07:56 UTC
-
New blood pressure cuff could replace needles for High-Risk C-Sections
Knowledge-focused TerminatedThis study tested a non-invasive blood pressure monitor (CNAP) against the standard invasive method (using a needle in the artery) in 20 pregnant women with placenta accreta undergoing scheduled C-sections. The goal was to see if the gentler method gives equally accurate readings…
Sponsor: Beth Israel Deaconess Medical Center • Aim: Knowledge-focused
Last updated Jun 27, 2026 07:55 UTC
-
Simple 5-Minute exam may spot hidden pelvic damage after cancer radiation
Knowledge-focused TerminatedThis study aimed to find a better way to detect pelvic floor problems caused by radiation treatment for gynecologic cancer. Researchers tested a 5-minute single-digit pelvic exam on 22 patients undergoing chemoradiotherapy for cervical cancer. The goal was to see if this exam cou…
Phase: NA • Sponsor: Washington University School of Medicine • Aim: Knowledge-focused
Last updated Jun 27, 2026 07:54 UTC
-
Scientists track HPV's secret life in young women
Knowledge-focused TerminatedThis study followed 190 young women to learn how the body handles new HPV infections. Researchers measured virus levels, immune cells, and other factors over time. The goal was to understand why some infections clear quickly while others persist. No treatment was given; this was …
Phase: NA • Sponsor: University Hospital, Montpellier • Aim: Knowledge-focused
Last updated Jun 27, 2026 07:53 UTC
-
Can genetic testing help men with metastatic prostate cancer?
Knowledge-focused TerminatedThis study offered genetic testing to men whose prostate cancer has spread to other parts of the body. Participants provided saliva samples to check for inherited mutations in about 30 cancer-risk genes. The goal was to understand how often these mutations occur and how men feel …
Sponsor: University of Washington • Aim: Knowledge-focused
Last updated Jun 27, 2026 07:52 UTC
-
HIV study tracks daily movement in NYC
Knowledge-focused TerminatedThis study looked at how much physical activity and sitting time people with HIV in New York City get. Participants wore a small device called an accelerometer for a week to track their movement. The goal was to understand how activity levels relate to overall health. The study w…
Sponsor: Queens College, The City University of New York • Aim: Knowledge-focused
Last updated Jun 27, 2026 07:52 UTC
-
Which radioactive drug hits tumors harder? small study aims to find out
Knowledge-focused TerminatedThis early-phase study compared two radioactive drugs, lutetium rhPSMA-10.1 and Pluvicto, in 17 men with metastatic prostate cancer that cannot be cured. The goal was to see which drug delivers more radiation to tumors and less to healthy organs like the kidneys. The study was te…
Phase: EARLY_PHASE1 • Sponsor: Blue Earth Therapeutics Ltd • Aim: Knowledge-focused
Last updated Jun 27, 2026 07:52 UTC
-
HIV drugs may weaken bones: new study investigates
Knowledge-focused TerminatedThis study looked at bone density in HIV-positive men to see if antiretroviral drugs cause bone thinning. Researchers compared men starting HIV treatment with those not yet on therapy over two years. The goal was to understand why bone loss is more common in HIV patients.
Phase: NA • Sponsor: University Hospital, Strasbourg, France • Aim: Knowledge-focused
Last updated Jun 27, 2026 07:51 UTC
-
Penile cancer data dive: no treatment, just facts
Knowledge-focused TerminatedThis study aimed to gather information from about 500 people with penile cancer to better understand the disease, its risk factors, treatments, and outcomes. Researchers did not provide any new treatment or intervention. The study was stopped early, but the data collected may hel…
Sponsor: M.D. Anderson Cancer Center • Aim: Knowledge-focused
Last updated Jun 27, 2026 07:51 UTC
-
Pregnancy registry for elagolix users launched, then stopped early
Knowledge-focused TerminatedThis registry aimed to track pregnancy outcomes in women who were exposed to elagolix (brand names Orilissa and Oriahnn) for endometriosis or uterine fibroids. The study planned to enroll 584 pregnant women, half with elagolix exposure and half without, and follow them through pr…
Sponsor: AbbVie • Aim: Knowledge-focused
Last updated Jun 26, 2026 16:55 UTC
-
Experimental immune drug tested in HPV cancers – but trial halted early
Knowledge-focused TerminatedThis very early trial tested a single dose of HB-201 in 10 people with HPV 16+ throat or cervical cancer. The goal was to see how the drug affects the immune system, not to treat the cancer. The study was terminated early, so results are limited.
Phase: EARLY_PHASE1 • Sponsor: Hookipa Biotech GmbH • Aim: Knowledge-focused
Last updated Jun 26, 2026 16:31 UTC
-
Blood test could spot cervical cancer spread early
Knowledge-focused TerminatedThis study looked at whether tumor DNA floating in the blood of cervical cancer patients can help detect early spread of the disease. Researchers took blood samples from 26 patients before, during, and after treatment. The goal was to see if this DNA test could find minimal metas…
Phase: NA • Sponsor: Institut Curie • Aim: Knowledge-focused
Last updated Jun 26, 2026 14:53 UTC